JPH0441000B2 - - Google Patents
Info
- Publication number
- JPH0441000B2 JPH0441000B2 JP60229763A JP22976385A JPH0441000B2 JP H0441000 B2 JPH0441000 B2 JP H0441000B2 JP 60229763 A JP60229763 A JP 60229763A JP 22976385 A JP22976385 A JP 22976385A JP H0441000 B2 JPH0441000 B2 JP H0441000B2
- Authority
- JP
- Japan
- Prior art keywords
- prothrombin
- abnormal
- patients
- antigen
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229940039716 prothrombin Drugs 0.000 claims abstract description 220
- 108010094028 Prothrombin Proteins 0.000 claims abstract description 218
- 102100027378 Prothrombin Human genes 0.000 claims abstract description 218
- 101000651439 Homo sapiens Prothrombin Proteins 0.000 claims abstract description 10
- 229940039715 human prothrombin Drugs 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims description 22
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 9
- 229910001424 calcium ion Inorganic materials 0.000 claims description 9
- 108010063628 acarboxyprothrombin Proteins 0.000 claims description 6
- 239000000523 sample Substances 0.000 claims description 5
- 239000012472 biological sample Substances 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 description 120
- 239000000427 antigen Substances 0.000 description 46
- 102000036639 antigens Human genes 0.000 description 44
- 108091007433 antigens Proteins 0.000 description 44
- 210000002966 serum Anatomy 0.000 description 36
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 30
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 229930003448 Vitamin K Natural products 0.000 description 17
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 17
- 235000019168 vitamin K Nutrition 0.000 description 17
- 239000011712 vitamin K Substances 0.000 description 17
- 150000003721 vitamin K derivatives Chemical class 0.000 description 17
- 229940046010 vitamin k Drugs 0.000 description 17
- 201000000839 Vitamin K Deficiency Bleeding Diseases 0.000 description 16
- 206010047634 Vitamin K deficiency Diseases 0.000 description 16
- 208000016794 vitamin K deficiency hemorrhagic disease Diseases 0.000 description 16
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 15
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 15
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 15
- 238000003556 assay Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 208000019423 liver disease Diseases 0.000 description 12
- 229960005080 warfarin Drugs 0.000 description 11
- 208000035475 disorder Diseases 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 206010008909 Chronic Hepatitis Diseases 0.000 description 8
- 206010019755 Hepatitis chronic active Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000006454 hepatitis Diseases 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 238000003127 radioimmunoassay Methods 0.000 description 8
- 208000002672 hepatitis B Diseases 0.000 description 7
- 238000002271 resection Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 230000001594 aberrant effect Effects 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 230000035602 clotting Effects 0.000 description 5
- UHBYWPGGCSDKFX-VKHMYHEASA-N gamma-carboxy-L-glutamic acid Chemical compound OC(=O)[C@@H](N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-VKHMYHEASA-N 0.000 description 5
- 230000001771 impaired effect Effects 0.000 description 5
- 201000007270 liver cancer Diseases 0.000 description 5
- 208000014018 liver neoplasm Diseases 0.000 description 5
- 230000003211 malignant effect Effects 0.000 description 5
- 229940019333 vitamin k antagonists Drugs 0.000 description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- 231100000354 acute hepatitis Toxicity 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000023555 blood coagulation Effects 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 239000001110 calcium chloride Substances 0.000 description 4
- 235000011148 calcium chloride Nutrition 0.000 description 4
- 229910001628 calcium chloride Inorganic materials 0.000 description 4
- 230000021523 carboxylation Effects 0.000 description 4
- 238000006473 carboxylation reaction Methods 0.000 description 4
- 230000007882 cirrhosis Effects 0.000 description 4
- 208000019425 cirrhosis of liver Diseases 0.000 description 4
- 229940072645 coumadin Drugs 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 231100000283 hepatitis Toxicity 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 208000037819 metastatic cancer Diseases 0.000 description 4
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 4
- KYITYFHKDODNCQ-UHFFFAOYSA-M sodium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [Na+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 KYITYFHKDODNCQ-UHFFFAOYSA-M 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 229960002647 warfarin sodium Drugs 0.000 description 4
- 101000651448 Bos taurus Prothrombin Proteins 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 2
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 206010064912 Malignant transformation Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 238000000760 immunoelectrophoresis Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 230000036212 malign transformation Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000000439 tumor marker Substances 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241000122860 Echis carinatus Species 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 102000004641 Fetal Proteins Human genes 0.000 description 1
- 108010003471 Fetal Proteins Proteins 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101000882917 Penaeus paulensis Hemolymph clottable protein Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003698 antivitamin K Substances 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000004597 appetite gain Effects 0.000 description 1
- 159000000009 barium salts Chemical class 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000013357 binding ELISA Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- UHBYWPGGCSDKFX-UHFFFAOYSA-N carboxyglutamic acid Chemical compound OC(=O)C(N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-UHFFFAOYSA-N 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000010235 enterohepatic circulation Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 230000006624 extrinsic pathway Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000001515 vagal effect Effects 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3038—Kidney, bladder
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/807—Apparatus included in process claim, e.g. physical support structures
- Y10S436/808—Automated or kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/815—Test for named compound or class of compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/825—Pretreatment for removal of interfering factors from sample
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
ããããã³ãã³ã¯ããªã以åããç¥ãããŠãã
ããã«è¡æ¶²ååºã®æçµæ®µéã«é¢äžãããã¿ãã³ïŒ«
äŸåæ§è¡æŒ¿èçœè³ªã§ãããããã¯çŽ72000ã®åå
éããã¡ãçŽ12ïŒ ã®çæ°Žåç©ãå«æãããããã
ãã³ãã³ã¯æ¢ç¥ã®ãšããã«ã«ã·ãŠã ã®ååšäžã§ç«
äœé 座ãå€åããã«ã«ã·ãŠã çµåæ§èçœè³ªã§ã
ããããããã³ãã³ããããã³ãã³ãžã®èçœå解
ã䌎ã掻æ§åã¯æ£åžžãªæ¢è¡ã«ãããéèŠãªå·¥çšã§
ãããããããã³ãã³ã¯èèã§åæãããããã
ã§ããããã³ãã³åé§ç©è³ªã翻蚳åŸä¿®é£Ÿãåã
ãŠãããããã³ãã³ã®æ©èœåœ¢ã«ãªããããã¯â倩
ç¶ããããã³ãã³âãšããŠç¥ãããγâã«ã«ãã
ã·ã°ã«ã¿ãã³é žãå«æããããã¿ãã³ïŒ«æ®æè¬ã
ããšãã°ã¯ã«ãã¢ãªã³ãããªãŠã ïŒãã©ãŠãšã¢å·
ãŠã€ã«ãã³ãã³ã®ããŠãã³ç€Ÿãšã³ãã»ã©ãã©ããª
ãŒãºéšéã®åæšã¯ããžã³ïŒCoumadinïŒãæãã
補åãšããŠãç¥ãããŠããïŒã®ååšäžã§ããŸãã¯
ãã¿ãã³ïŒ«ã®äžåšäžã§ãè¡äžã®ããããã³ãã³æŽ»
æ§ã¯ææã«äœäžããå¯èœæ§ããããããã¯ããã
ãã³ãã³æéïŒäžæ®µåè¡ã¢ãã»ã€æ³ïŒã«ããéæ¥
çã«ããŸãã¯ããããã³ãã³æ¬ æåºè³ªè¡æŒ¿ãçšã
ãããããã³ãã³åè¡æŽ»æ§ã®çŽæ¥æž¬å®ã«ãã枬å®
ããããšãã§ãããè¡æŒ¿ããããã³ãã³æŽ»æ§ãäœ
ãå Žåãéçã®èçŸæ£ã䌎ãå¯èœæ§ããããããš
ãã°èçœè³ªåæé害ïŒèçŸæ£ïŒãäžé©åœãªãã¿ã
ã³ïŒ«äŸçµŠïŒãã¿ãã³ïŒ«æ¬ ä¹çïŒããŸãã¯ãã¿ãã³
ã®äœçšãææ¢ããè¬ç©ïŒã¯ã«ãã¢ãªã³ãããªãŠ
ã ïŒã¯ãããã®ä»ã®åºä¹³é¡ã«ãããè¡æŒ¿ãããã
ã³ãã³æŽ»æ§ãäœäžãããã ã¯ããžã³ã¯ã¯ã«ãã¢ãªã³ã®åååã§ãããã¯ã
ãžã³ãè¡æ æ§çŸæ£ã®æ²»çãŸãã¯äºé²ã«éãåºãè¡
ãããŠããããã«çµå£æåè¡è¬ãšããŠçšãããšã
ããã¯ãã¿ãã³ïŒ«äŸåæ§è¡æ¶²ååºèçœè³ªãããšã
ã°ããããã³ãã³ã®æŽ»æ§ãäœäžããããé©åãªã¯
ããžã³çšéã¯ããããã³ãã³æéã®ç£èŠã«ãã確
ç«ããããããããã³ãã³æéã¯æ£åžžãªè¡æŒ¿ã«é¢
ããŠåŸãããæéã®ïŒ1/2ãïŒïŒ1/2åã«ç¶æãã
ãã 1968幎ã«ãã¯ã«ãã¢ãªã³ãããªãŠã ã§æ²»çãã
æ£è ã®è¡æŒ¿äžã«ããã倩ç¶ããããã³ãã³ã«å¯Ÿæ¯
ããŠâç°åžžããããã³ãã³âããã³âããç°åžžã
ãããã³ãã³âãšããŠç¥ãããããããã³ãã³ã®
å€åœ¢ãçºèŠããããç°åžžããããã³ãã³ããã€ã
ãããã³ãã³æŽ»æ§ã¯äœãããå€æ°ã®ããããã³ã
ã³æè¡æž ãšäº€ååå¿ããããŠã·è¡æ¶²ããç°åžžãã
ããã³ãã³ã1972幎ã«åããŠåé¢ãããããã®çš®
ã®ç°åžžããããã³ãã³ã¯çéã®å€©ç¶ããããã³ã
ã³ã®çŽïŒïŒ ã®åè¡æŽ»æ§ããã€ããšãèªããããã
ãã®ã»ãååéãé žå æ°Žå解ã®çæ°Žåç©çµæãã
ã³ã¢ããé žçµæã¯å®è³ªçã«å®éšèª€å·®ã®ç¯å²å ã§ç
ããã€ãã1970幎代åæã«ãŠã·ç°åžžããããã³ã
ã³ã¯ããããã³ãã³ãšç°ãªãããªãŠã å¡©ã«çµåã
ããã«ã«ã·ãŠã ã€ãªã³ã«çµåããªãããšãèŠåºã
ããããã®åŸãç°åžžããããã³ãã³ãšå€©ç¶ããã
ãã³ãã³ãšã®æ©èœäžã®çžéã¯ãããã®èçœè³ªéã®
æ§é äžã®çžéã«é¢ä¿ããããå®å šãªããããã³ã
ã³æ©èœã«ã¯ç¡å·ã®ã«ã«ã·ãŠçµåéšäœãå¿ èŠãšãã
ããšã瀺ãããã1970幎代äžæã«ããããŸã§ç¥ã
ããŠããªãã€ãã¢ããé žã§ããγâã«ã«ããã·ã°
ã«ã¿ãã³é žããŠã·ããããã³ãã³äžã«ååšããã
ããç°åžžãŠã·ããããã³ãã³ã«ã¯æ¬ åŠããŠããã
ãšãèŠåºãããããã®ã¢ããé žã¯ããããã³ãã³
ã®åè¡æŽ»æ§ãå®å šã«çºçŸããããã«å¿ èŠã§ãããš
æããããç°åžžããããã³ãã³ã¯åè¡æŽ»æ§ããã
ãªãããšãç¥ãããŠãããéå±ã€ãªã³ãçµåã
ããγâã«ã«ããã·ã°ã«ã¿ãã³é žãå«ãŸãªããä»
ã®ç 究è ãã¯ãããããã³ãã³ãèèå ã§Î³âã«
ã«ããã·ã°ã«ã¿ãã³é žã®ä»£ããã«ã°ã«ã¿ãã³é žã
å«æããåé§ç©è³ªã®åœ¢ã§åæãããããšçè«ã¥ã
ããèèå ã§ã®ã«ã«ããã·ã«åéçšã§ã°ã«ã¿ãã³
é žã修食ãããŠÎ³âã«ã«ããã·ã°ã«ã¿ãã³é žã圢
æãããããã®é µçŽ ç³»ã¯ãã¿ãã³ïŒ«ãå¿ èŠãšãã
ãã¿ãã³ïŒ«æ®æè¬ã«ããæå¶ãããã äœæ¶²ãããšãã°è¡æŒ¿äžã®ããããã³ãã³ããã³
ç°åžžããããã³ãã³ã®æ°Žæºã枬å®ããããã®å®é
çã¢ãã»ã€æ³ãéçºããããã«ããããŸã§å€ãã®
åªåããªãããŠããããããã®æ¹æ³ã«ã¯ãããŸã§
èããå¶éããã€ããããç°åžžããããã³ãã³ã
ãã³ãã倩ç¶ããããã³ãã³ã¯å ±ã«584åã®ã¢ã
ãé žãå«ã¿ããããã®ãã¡574åã¯ãããïŒåœ¢æ
ã«ãããŠçãããæ®ãã®10åã¯ã«ã«ããã·ã«åºã«
ãããŠç°ãªãã«ãããªããšããç¹ã§ãã¢ãã»ã€æ³
ãèæ¡ããããšã¯å°é£ã§ãã€ãããããã®èçœè³ª
ã¯ãæ§é äžã¯ã»ãŒçãããæ©èœçé¢äžã«ãããŠã¯
ããããŠç°ãªã€ãŠãããè¡æ¶²ååºã«é¢ããŠç°ãªã
圹å²ããã€ã è¡æ¶²ååºã®å€å æ§çµè·¯ã«ãããããããã³ãã³
ããã³ä»ã®èçœè³ªãè©äŸ¡ããããã®æ¢åã®æ¹æ³ã«
ã¯ãäžè¬çãªããããã³ãã³æé枬å®æ³ãå«ãŸã
ããããã¯ç°åžžããããã³ãã³æ°Žæºãæ€åºããã
ã®ã§ã¯ãªããããããã³ãã³ã®åè¡æŽ»æ§ã®çŽæ¥ã¢
ãã»ã€ã¯ã被éšè¡æŒ¿ãçš®ã ã®å²åã®ããããã³ã
ã³æ¬ æè¡æŒ¿ãšæ··åãã次ãã§åè¡ãããæšæºæ²ç·
ãšæ¯èŒããããšã«ããè¡ãããã倩ç¶åã®æ©èœæ§
ããããã³ãã³ã®ã¿ã枬å®ãããã亀åå ç«é»æ°
æ³³åæ³ã¯ç°åžžããããã³ãã³ããã³å€©ç¶ãããã
ã³ãã³ã®åæ¹ãæºå®éçã«æž¬å®ããããäŸäžçš®ã
ä»æ¹ãé èœããã®ãé²ãããã«ã¯åæ§ãªæ¿åºŠã§ã
ãããšãå¿ èŠã§ãããåŸã€ãŠçšéãéå®ãããã
ä»ã®å é£ãªãã€æè¡ãèŠããè©Šéšæ³ã¯ããŒã¬ã«
ïŒLaurellïŒã®ãã±ããå ç«é»æ°æ³³åæ³ã§ãããã
ãã¯äžèšïŒçš®ã®ããããã³ãã³ãåºå¥ã§ããªãã
ããããã³ãã³ã®ã©ãžãªã€ã ãã¢ãã»ã€ãè¡ãã
ããããããŸã§ã«çšããããæäœã¯ç°åžžãããã
ã³ãã³ã«ãæ£åžžããããã³ãã³ã«ãåçã«ïŒãŸã
ã¯ã»ãšãã©åçã«ïŒçµåããåŸã€ãŠç·ããããã³
ãã³æ°Žæºã枬å®ãããã«ããããèšåºèšºæçšãšã
ãŠã¯äžååã§ãããèæ¯ãçšãããšãã¹ã»ã«ãªã
ãŒã¿ã¹ïŒæ¯èã®äžçš®ãEchis carinatusïŒã¢ãã»
ã€æ³ã¯ç·ããããã³ãã³ã®æž¬å®ã«çšãããããäº
段ããããã³ãã³ã¢ãã»ã€æ³ãšçµåããŠãããã®
ã¢ãã»ã€ãéæ¥çã«ç°åžžããããã³ãã³æ°Žæºã®æš
å®ã«çšããããšãã§ããã äžèšã¢ãã»ã€æ³ã®ãããããç¹ã«ããã«ãããŠ
ç°åžžããããã³ãã³ã®ååšäžã§ã®ããããã³ã
ã³ããããã¯æ£åžžããããã³ãã³ã®ååšäžã§ã®ç°
åžžããããã³ãã³ã«é¢ããçŽæ¥çãå®éçãªã容
æã«å®æœãããæ床ã®é«ãç¹ç°çã¢ãã»ã€æ³ãæ
äŸããªããæ¬çºæã«ãããŠã¯èçœè³ªè¡šé¢ã®ç¹å®é
åã«å¯Ÿããç«äœé 座ç¹ç°æ§æäœãçšããç 究ãè¡
ãããã®çµæç°åžžããããã³ãã³ã«å¯ŸããŠããã
ã³å€©ç¶ããããã³ãã³ã«å¯ŸããŠç¹ç°çãªå ç«ååŠ
çè©Šè¬ãéçºããããç°åžžããããã³ãã³ããã³
倩ç¶ããããã³ãã³ã被éšåºä¹³åç©ããåŸããã
è¡æž æ€äœã®ãã®ã§ããæ¹æ³ãèšè¿°ãããããã«ã
ãåºä¹³åç©è¡æŒ¿äžã®ç°åžžããããã³ãã³ãŸãã¯å€©
ç¶ããããã³ãã³ã®æ°Žæºã枬å®ãããããã«ãã
ãŠã¯ç°åžžããããã³ãã³ã®ååšã¯èº«äœã®é害ã瀺
ãã奜ãŸãã圢æ ã«ãããŠã¯ãããã®ç°åžžããã
ãã³ãã³ããã³æ£åžžããããã³ãã³ã®æž¬å®ã¯ä»æ¹
ã®ååšäžã§ããããã«å¯Ÿãç¹ç°çãªæäœã®äœ¿çšã«
ãã€ãŠè¡ãããã身äœã®é害ããã¿ãã³ïŒ«æ¬ ä¹ç
ã§ããå Žåãç°åžžããããã³ãã³ã®æ°Žæºãç£èŠã
ãããããããå®ããããæ°Žæºã«ç¶æãããã奜
ãŸããã¯æåè¡è¬ã®æäžãããšãã°ã¯ã«ãã¢ãªã³
ã®æäžãèŠæ±ãããå Žåãæäžããã¯ã«ãã¢ãªã³
ã®ç®çæ°Žæºãªããã¯ç®çéãæ瀺ãããã®ãšããŠ
倩ç¶ããããã³ãã³ãç£èŠããã倩ç¶ããããã³
ãã³ã®æ°Žæºããã®æ¹æ³ã§å®éçã«æž¬å®ããããšã
ã§ãããããã®ãã¿ãã³ïŒ«æ®æè¬ïŒããšãã°ã¯ã«
ãã¢ãªã³ïŒã«ããæåè¡çæ³æéäžããããã®æ°Ž
æºãå®éçã«æž¬å®ããã®ã¡12ã24ÎŒïœïŒmlã®å€©ç¶
ããããã³ãã³æ°Žæºãã䜿çšäžã®è¬ç©ïŒããšãã°
ã¯ã«ãã¢ãªã³ãããªãŠã ïŒãããã«æäžããããš
ã«ããç¶æãããã奜ãŸããã¯å€©ç¶ããããã³ã
ã³ã¯10ã24ÎŒïœïŒmlã®äœæ¶²å æ°Žæºã«ç¶æãããã æ¬çºæã«ããã°ãã倩ç¶ããããã³ãã³ããã³
ã«ã«ã·ãŠã ã®ååšäžãã¹âγâã«ã«ããã·ãã
ïŒããªãã¡ç°åžžïŒããããã³ãã³ãšåå¿æ§ã§ããã
ã«ã«ã·ãŠã ã€ãªã³ã®ååšäžã§ãã倩ç¶ããããã³
ãã³ãšã¯å®è³ªçã«éåå¿æ§ã§ããã¢ãã¯ãâãã«
æäœãæäŸãããã ç°åžžããããããã³ãã³ã«å¯Ÿããããªã¯ããŒã
ã«æäœãšç°ãªãæ¬çºæã®ã¢ãã¯ããŒãã«æäœã¯ã«
ã«ã·ãŠã ã€ãªã³ã®äžåšäžã§ãã倩ç¶ããããã³ã
ã³ãšè€åäœã圢æãããå©ç¹ããã€ãæ¬çºæã®ã¢
ãã¯ããŒãã«æäœã¯ãã€ã³ãããè©Šéšçšäœæ¶²äžã§
æšæºçãªå®éšå®€æ¡ä»¶äžãããšãã°å®€æž©ãæšæºç倧
æ°å§ãããã³ãããã®æ®éã®å€åã«ãããŠåå¿æ§
ã§ãããè€åäœã圢æããç¹ã§å¥œãŸããã å®éçããã³å®æ§ç枬å®å€ãåŸãããã®ã€ã ã
ã¢ãã»ã€ãè¡ãæ¹æ³ã«ãããŠã¯ãäžè¬çãªã€ã ã
ã¢ãã»ã€æäœæ³ãæ¡çšããããšãã§ããããã«ã¯
é µçŽ çµåã¢ãã»ã€æ³ããã³ã©ãžãªã€ã ãã¢ãã»ã€
æ³ãå«ãŸããã ããç°åžžããããã³ãã³ã®ååŠã¯ãè¡æŒ¿ãŸãã¯
è¡æž è©Šæã«ã€ããŠåèšã®é©å®ãªã¢ãã¯ããŒãã«æ
äœãšã®å ç«åå¿ãè¡ãªãããããŠæäœâæåè€å
äœã®ååŠãåžžæ³ã«ããå®æ§çãŸãã¯å®éçã«æž¬å®
ããããšã«ãã€ãŠæž¬å®ãããã 人äœå ã«ãããããç°åžžããããã³ãã³ã®ååš
ã¯ãèçŸæ£ç¶æ ã«ããå Žåãåäœããã¿ãã³ïŒ«æ®
æè¬ãªã©ã®ç©è³ªã§åŠçããå Žåããã¿ãã³ïŒ«æ¬ ä¹
ã®å ŽåããŸãã¯ã«ã«ããã·ã«åé害ããããã代
è¬æ¬ é¥ã®çµæ以å€ã¯ãè¡æŒ¿ãè¡æž ãŸãã¯ä»ã®äœæ¶²
ïŒmlåœãã0.03ÎŒïœãè¶ããããšã¯ãªããå®éã«
ã¯æ¶²äœïŒmlåœãã0.03ÎŒïœä»¥äžã®æ°Žæºããã®çš®ã®
çŸæ£ã瀺ããã®ãšèãããããããã®ããã«äœã
æ°Žæºãæ¬çºææ¹æ³ã«ããæ¢ç¥ããããšã¯ã§ããª
ããç°åžžããããã³ãã³ã®ååšã¯ããããäžèšã®
çŸæ£ããã³é害ã瀺åãããã®ãšèãããããåŸ
ã€ãŠã€ã ãã¢ãã»ã€æ³ãçšããŠç¹å®ã®èçŸæ£ã®å
åŠãå€å®ããèçŸæ£ãç°åžžããããã³ãã³ãæ£åžž
ãªç¶æ ããå€åããŠããç¹å®ã®ä»ã®èº«äœæ©èœäžå š
ãšåºå¥ãããŸãæ£è ã«æäžããã¯ã«ãã¢ãªã³ãã
ãªãŠã ã®éã決å®ããŠè¡æ çãŸãã¯åºè¡ã®å±éºæ§
ãæå°éã«æããããšãã§ããã 第ïŒå³ã¯ãæ°çš®ã®å»åŠçé害ã䌎ãæ£è ã«ãã
ã倩ç¶ããããã³ãã³ããã³ç°åžžããããã³ãã³
ã®è¡æž æ¿åºŠã瀺ãã°ã©ãã§ããã 第ïŒå³ã¯ããã¿ãã³ïŒ«æ¬ ä¹çã䌎ãæ£è ã«ãã
ãŠãã¿ãã³ïŒ«çæ³ã倩ç¶ããããã³ãã³ããã³ç°
åžžããããã³ãã³ã«äžãã圱é¿ã瀺ãã°ã©ãã§ã
ãã 第ïŒå³ã¯ãè现èæ§çã䌎ãæ£è ã«ãããç°åžž
ããããã³ãã³ããã³å€©ç¶ããããã³ãã³ã®è¡æž
æ¿åºŠã瀺ãã°ã©ãã§ããã 第ïŒå³ã¯ãèçæ£è ïŒäººã«ãããç°åžžãããã
ã³ãã³ããã³Î±âããšããããã€ã³ã®è¡æž æ¿åºŠã
瀺ãã°ã©ãã§ããã 第ïŒå³ã¯ãïŒçš®ã®ç°ãªãèèé害ã䌎ãåæ£è
ã«ãããç°åžžããããã³ãã³ã®è¡æž æ¿åºŠã瀺ãã°
ã©ãã§ããã 第ïŒå³ã¯ãèçæ£è ã«ãããç°åžžããããã³ã
ã³ããã³Î±âããšããããã€ã³ã®è¡æž æ¿åºŠã瀺ã
ã°ã©ãã§ããã 第ïŒå³ã¯ãåçš®ã®å»åŠçé害ã䌎ãåæ£è ã®è¡
æž äžã«ãããç°åžžããããã³ãã³æ°Žæºã瀺ãã°ã©
ãã§ããã ããããã³ãã³çåæé害ã®æ€åºããã³èšºæã¯
ããã«ãããŠè¡æŒ¿ãŸãã¯è¡æž ã®ç°åžžããããã³ã
ã³ã®æž¬å®ã«ããè¡ãããšãã§ãããç°åžžãããã
ã³ãã³ã®ç¹ç°çã¢ãã»ã€ãããè¡æŒ¿ãŸãã¯è¡æž ã«
ãããŠæ¡çšããããããã³ãã³çåæã®ç¶æ ãå€
å®ããããã®æ å ±ã¯ç¹å®ã®çŸæ£ã®ç¶æ ãšãçžé¢ã
ãŠããå¯èœæ§ãããã çåžžè¡æŒ¿ïŒæ£åžžãªåäœããåŸãããè¡æŒ¿ããã³
è¡æž ã¯æ€åºå¯èœãªç°åžžããããã³ãã³ãå«ãŸãª
ãããã®ã¢ãã»ã€æ³ã®æ床ããã³ç¹ç°æ§ã¯ãç°åžž
ããããã³ãã³ã0.03ÎŒïœïŒml以äžãšãªãåŸãªã
ããšã瀺ããŠãããæ£åžžæ°Žæºã®å€©ç¶ããããã³ã
ã³ã¯çŽ108ÎŒïœïŒmlã§ããã æ¥æ§èçïŒæ¥æ§èçã䌎ãæ£è ããåŸãè¡æŒ¿ã
ãã³è¡æž ã¯0.1ã6ÎŒïœïŒmlãŸãã¯ãã以äžã«å€å
ãã倧éã®ç°åžžããããã³ãã³ãå«æããã倩ç¶
ããããã³ãã³ã®æ°Žæºã¯éåžžã¯æ£åžžã§ããããæ£
åžžãªããããã³ãã³ã®ç¯å²ãããé«ããŸãã¯äœã
ãªãå¯èœæ§ãããã 硬å€ïŒã¢ã«ã³ãŒã«è硬å€ã䌎ãæ£è ããåŸãè¡
挿ããã³è¡æž ã¯é«ãç°åžžããããã³ãã³ãå«ãã
ããããã³ãã³æ°Žæºã¯éåžžã¯æºæ£åžžã§ããã æ ¢æ§æŽ»åæ§èçïŒæ ¢æ§æŽ»åæ§èçã䌎ãæ£è ã
ãåŸãè¡æŒ¿ããã³è¡æž ã¯æ€åºå¯èœãªç°åžžãããã
ã³ãã³ãå«ãŸãªãã ãã¿ãã³ïŒ«æ¬ ä¹çïŒè žã«ããããã¿ãã³ïŒ«åžå
äžå šãè žè埪ç°é害ãæ é€æ¬ ä¹ããŸãã¯ææ§ç©è³ª
ã«ããè žå 现èã®åŠšå®³ã«åºã¥ããã¿ãã³ïŒ«æ¬ ä¹ç
ã¯ç°åžžããããã³ãã³ããã³ããã«çžåœãããã
ããã³ãã³äœäžã䌎ãããããã®æ£è ã¯ãã¿ãã³
ã«å¿çããã èèãå«ã転移æ§çïŒèèã®ç Žå£ãå«ãçã䌎
ãæ£è ã«ãããŠã¯ç°åžžããããã³ãã³æ°Žæºãé«
ãã è现èæ§çïŒç°åžžããããã³ãã³ãäžæ§ã«ååš
ãããæ°Žæºã¯äœãæ°ŽæºããããããŠé«ãæ°Žæºã«ãŸ
ã§å€åããã倩ç¶ããããã³ãã³ã®æ°Žæºã¯æ£åžžã§
ããããå€åããããã 蚺æã®è£äœã«ã¯äžèšã®ãã®ãå«ãŸããã (a) ç°åžžèæ©èœç 究ã«ããããããã³ãã³æéã®
延é·ã䌎ãæ£è ã¯ãèçŸæ£ãŸãã¯ãã¿ãã³ïŒ«æ¬
ä¹çãæããå¯èœæ§ããããé«æ°Žæºã®ç°åžžãã
ããã³ãã³ããã³äžçšåºŠã«äœãæ°Žæºã®ãããã
ã³ãã³ã¯ãã¿ãã³ïŒ«æ¬ ä¹çã瀺åãããäœãæ°Ž
æºã®ç°åžžããããã³ãã³ããã³æ£åžžãªæ°Žæºã®ã
ãããã³ãã³ã¯èçŸæ£ã瀺ãã (b) æ£è ã¯æ°åãæªããè¡æ¶²åŠçæ€æ»ããã³è ã¹
ã¯ãªãŒãã³ã°ãã¹ãã¯ãã¹ãŠæ£åžžã§ãããç°åžž
ããããã³ãã³æ°Žæºã®äžæã¯æœåšæ§èçŸæ£ã瀺
ãã (c) é»çžããã³èããåè¡é害ã䌎ãåºè¡æ§æ£è
ã¯ç°åžžããããã³ãã³ã®å¢å ã瀺ãããšãèªã
ããããããã¯èçŸæ£ã®èšºæã瀺ããã®ã§ã
ããè¡ç®¡å åè¡ã瀺ããã®ã§ã¯ãªãã (d) ããâæ£åžžãªâåäœãèããåºè¡ãçããã
ããããã³ãã³æéã延é·ããŠãããããããŠ
é«ãç°åžžããããã³ãã³ããã³äœãããããã³
ãã³ã¯ãã¯ã«ãã¢ãªã³ã®éå°æäžãããªãã¡äž
èªç¶ãªã¯ã«ãã¢ãªã³æåã瀺åããã (e) ïŒå¹Žåã«åçºæ§é»è²è «ã䌎ã€ãæ£è ãå šèº«å
ã®çç¶ãçºçŸããŠãããç°åžžããããã³ãã³ã®
å¢å ã¯çã®è浞最ã瀺åããã (f) ããæ£è ãåçºæ§è¡æ çã®æå¶ã®ããã¯ã«ã
ã¢ãªã³ã§æ²»çãããã倩ç¶ããããã³ãã³æé
ã¯æ²»çç¯å²ã«ããã«ããããããã倩ç¶ããã
ãã³ãã³ã¯36ÎŒïœïŒmlã§ãããšæž¬å®ããããã
ã®æ£è ã¯è¡æ çã®æãããããšèšºæããããã¯
ã«ãã¢ãªã³ã®ïŒæ¥éãé«ãã倩ç¶ããããã³ã
ã³ãå®æçã«ç£èŠããã ã¢ãã»ã€æ³ã«çšããããã®æ¬çºæã®æäœã®ãã€
ã¢ã«ãå«ãã€ã ãã¢ãã»ã€ããããçšæããããš
ãã§ãããããšãã°ããç°åžžããããã³ãã³ã«ç¹
ç°çãªæšèãããããŸãã¯æšèãããŠããªãæäœ
ã®ãã€ã¢ã«ãçšæããRIAãã®ä»ã®ã€ã ãã¢ãã»
ã€ãããã«çšããä»ã®ææãšå ±ã«å è£ ããããšã
ã§ããããã®çš®ã®ãããã«ãããææã®å®¹ç©ãã
ã³ãããã®æ§æéšåã®æ°ã¯å€§å¹ ã«å€ãããããã
ã®çš®ã®ãããã¯ãããã®æäœãšæåâæäœè€åäœ
ã圢æããæåã®ååŠããã³éã枬å®ããã€ã ã
ã¢ãã»ã€æ³ãå®æœããããã®æ瀺ãå ±ã«é åžãã
ãå Žåãå€ãã ãããã®å ç«ååŠç©è³ªãè©Šè¬ãšããŠçšããŠãã
ãè¡æŒ¿ãŸãã¯è¡æž äžã®ç°åžžããããã³ãã³ã«é¢ã
ãç¹ç°çã©ãžãªã€ã ãã¢ãã»ã€æ³ãéçºãããã
ãããã®ã©ãžãªã€ã ãã¢ãã»ã€æ³ã¯æšæºçãªäºé
æäœæ²æ®¿æ³ããã³æŸå°æ§ãšãŠçŽ åããæåã䌎
ããç°åžžããããã³ãã³ã«é¢ããã¢ãã»ã€æ³ã¯
2nïœïŒmlã«åã¶æ床ã瀺ããããããã³ãã³
150ÎŒïœã®ååšäžã§ã®ç°åžžããããã³ãã³æ€åºé
çã¯0.03ÎŒïœïŒmlã§ãããæ£åžžãªè¡æŒ¿ã¯ç°åžžãã
ããã³ãã³ãå«ãŸãªããäœæ°ŽæºïŒ0.2ã8ÎŒïœïŒmlïŒ
ã®ç°åžžããããã³ãã³ã¯çš®ã ã®èçŸæ£ã«ç¹åŸŽçã§
ããïŒèçã硬å€ã転移æ§æªæ§çãåçºæ§è现è
æ§çïŒã察å¿ããäœãããããã³ãã³ã䌎ãäœæ°Ž
æºãªããã¯é«æ°Žæºã®ç°åžžããããã³ãã³ïŒïŒã
100ÎŒïœïŒmlïŒã¯ãã¿ãã³ïŒ«æ¬ ä¹ã®çšåºŠãšé¢é£ã
ããã¯ã«ãã¢ãªã³ãããªãŠãæåããŠããæ£è ã¯
35ÎŒïœïŒmlã®ç¯å²ã®ç°åžžããããã³ãã³æ°Žæºãã
ãã³10ã30ÎŒïœïŒmlã®ããããã³ãã³æ°Žæºãã
ã€ããã®ç°åžžããããã³ãã³ããã³ããããã³ã
ã³ã®æž¬å®ã«ããããã¿ãã³ïŒ«äŸåæ§ã«ã«ããã·ã«
åã®é害ãç¹è²ãšããçŸæ£ã䌎ãæ£è ã確èªã
ïŒã¹ã¯ãªãŒãã³ã°ãïŒã蚺æããããšãã§ãããã
ããã®æž¬å®ãçµå£æåè¡è¬çæ³ã®ç£èŠããã³å¶åŸ¡
ã«çšããããšãã§ãããæåŸã«ããããçšããŠãŠ
ããããã³ãã³åæã®é害ãšããããã³ãã³ç°å
å éïŒã¯ãªã¢ã©ã³ã¹ã®é害ãåºå¥ããããšãã§ã
ãã è©Šéšã¯æ®éã¯è¡æž ãŸãã¯è¡æŒ¿äžã§è¡ããããã
ãããå šè¡äžã§è¡ã€ãŠçžåœããçµæãåŸãããšã
ã§ããã ã¯ã«ãã¢ãªã³ç£èŠã«ã€ããŠèšè¿°ããããä»ã®ã
ã¿ãã³ïŒ«æ®æè¬ããã³æåè¡è¬ããã¯ã«ãã¢ãªã³
ã®çµå£äœ¿çšã®ç£èŠã«é¢ããæ¬çºææ¹æ³ã«åŸã€ãŠç£
èŠããå Žåãåæ§ãªçµæãåŸããããæ°çš®ã®å»åŠ
çé害ã䌎ãåæ£è ã®è¡æž äžã«ãããç°åžžããã
ãã³ãã³æ°Žæºã第ïŒå³ã«ç€ºãã ç°åžžããããã³ãã³ã«å¯Ÿããã¢ãã¯ããã«æäœã®
調補 ãã«ãïŒïœç³»ããŠã¹ããå®å šåããã€ã³ãã®ã¢
ãžãŠãã³ãäžã«25ÎŒïœã®ããç°åžžããããã³ãã³
ãæ··åãããã®ãç®äžæ³šå°ããŠå ç«ããã30æ¥ã
ãã³37æ¥åŸã«ã10ÎŒïœã®ç°åžžããããã³ãã³ãã
é£å¡©æ°Žäžã«æ³šå ¥ãããå ç«ãããããŠã¹ã®èŸè现
èïŒïŒÃ107ïŒãšSp2ïŒïŒè¡æŒ¿çŽ°èç³»ïŒïŒÃ106ïŒ
ãšã®èåã¯ã28ïŒ ããªãšãã¬ã³ã°ãªã³ãŒã«2000ã
çšããŠ0.5mläžã§ïŒåéè¡ã€ããèåãã现èãã
ããããµã³âã¢ããããªãã³âãããžã³ãå«ã
ïŒæçµæ¿åºŠã¯ããããã1.36ïŒ0.176ïŒããã³0.38
mgïŒmlïŒRPMI 1640ïŒ20ïŒ ä»ãŠã·è¡æž ã«æžæ¿ãã
ãŠãšã«ãããïŒâïŒÃ105ã®çŽ°èæ¿åºŠã§æ¥çš®ããã
æ¥çš®ãã540ã®ãŠãšã«ã®43ïŒ ã«çŽ°èã®çè²ã芳å¯
ãããã现èãæ°é±éå¹é€åŸãã³ãããŒãå«ããŠ
ãšã«ããäžæž ãåžåŒãã該äžæž ã«ã€ããŠæãã¹â
γâã«ã«ãã ããã³ãã³æäœæŽ»æ§ãã¢ãã»ã€ã
ããéœæ¥µã®ãŠãšã«ã®çŽ°èãéžæããŠå¶éåžéæ³ã«
ããã¯ããŒã³åãããããŠåãæ¹æ³ã«ããåã¯ã
ãŒã³åããã æç°åžžããããã³ãã³æäœãåæ³ãã现èã¯ã
ç°åžžããããã³ãã³ãšå€©ç¶ããããã³ãã³ïŒä»¥
äžãåããããã³ãã³ïŒãçšããïŒåã®åºçžã€ãŒ
ã©ã€ã¶ïŒELISAïŒæ³ã§åå®ãããããããã³ã
ã³ãšãããç°åžžåããããã³ãã³ãšãã€ãšå€§ããª
åå¿æ§ã瀺ãåã¯ãéå®åžéã«ãã€ãŠã¯ããŒã³å
ãããJO1âïŒãšåœåãããã¯ããŒã³ã¯ãç°åžžã
ãããã³ãã³ã«ã¯çµåãããåããããã³ãã³ãš
ã¯æ¥µå ãåå¿ããã ãã®æäœãçæãããã¢ãã¯
ããã«æäœã¯ãåç¹ç°æ§è¡æž ãçšãããªã¯ã¿ãã
ãŒã®å ç«æ¡æ£æ³ã«ããIgG1ãšããŠå®çŸ©ãããã ã¯ããŒã³JO1âïŒã¯ATCCã«å¯èšãããHB
8638ãšããåå ¥çªå·ãä»ããããã åºé¡äººã®è²å人ã§ããããŠãŒã€ã³ã°ã©ã³ãã¡ã
ã€ã«ã«ã»ã³ã¿ãŒã¯ããã®å¹é€ç©ãçºè¡ãããç¹èš±
ã®åç¶æéã®çµäºåã«å ã«æ»ããæ»ã¬ããã«ãã
矩åãè² ããäžã€ãããç¹èš±ã®çºè¡ãATCCã«å±
ããŠãã®æç¹ã§å¯èšç©ãå¯èšæ¥ããå°ãªããšã30
幎éã¯å ¬è¡ã®çšã«äŸãåŸãããã«ãã矩åãè²
ããäžèšæç¹ãŸã§ã¯ãå¯èšç©ã¯ã37 CFR1.14ç¯
ããã³ç±³åœç¹èš±æ³112ç¯ã®æ¡ä»¶ã®äžã«ç¹èš±å±é·å®
ãžæäŸãããã JO1âïŒæäœã®ç²Ÿè£œ ã«ã«ã·ãŠç¡ãã®ç°åžžããããã³ãã³ã«ç¹ç°çãª
JO1âïŒã¯ã次ã®ããã«è¡ã€ããããããã³ãã³
ããèåã·ã¢ã³ã§æŽ»æ§åããã»ãã¢ããŒã¹
ïŒSepharoseïŒ4Bã«ã¿ã³ãã¯è³ªïŒæš¹èéãïŒmgïŒ
mlã§ã«ãããªã³ã°ããããïŒæ¬ã®ã¢ãã€ããã€ã«
ã©ã ãçšæããŠãïŒããªã¢ã«ã®EDTAã®ååšãŸ
ãã¯äžåšã§ããããã³ãã³ãã«ãããªã³ã°ãã
ãã JO1âïŒå¹é€ç©äžæž 液ãã¢ãã³ã³ïŒAmiconïŒ
PM30èã§40åã«æ¿çž®ããTBSïŒEDTAïŒïŒããª
ã¢ã«ïŒäžã«éæããããã®ç©è³ªïŒ1.5mlïŒã
TBSïŒEDTMïŒïŒmlïŒãšå¹³è¡¡ã«ããåŸããããã
ããããã³ãã³âã»ãã¢ããŒã¹ ã«ã©ã ïŒ1.0Ã
2.3cmïŒã«å ãããçµåããæäœã¯ãåãç·©è¡æ¶²
ã§ïŒæéå¹é€ããåŸãTBSïŒCa++ïŒ15ããªã¢ã«ïŒ
ã§æº¶åºããã ããããã³ãã³çµå掻æ§ããçŽæ¥çµåã€ãŒã©ã€
ã¶ïŒELISAïŒæ³ã«ãã€ãŠæž¬å®ãããæäœèª¿è£œç©
ã®é£ç¶åžé液ãããæšæºæ²ç·ãäœæããã粟補ã
ãã¢ãã¯ããã«æäœã也ç¥ã¹ã¯ããŒã¹ãçšããŠã
éæ管äžã§æ¿çž®ãã8.75ïŒ SDS ããªã¢ã¯ãªã«ã¢
ããã²ã«äžã§çŽåºŠã枬å®ãããåé¢ãããJO1â
ïŒæäœã¯ãSDSããã³ããŒãã¹ïŒDavisïŒã²ã«é»
æ°æ³³åæ³ã§ã¯åäžãã³ããšããŠç§»åããã æäœâããããã³ãã³çžäºäœçšã«å¯ŸããïŒäŸ¡éœã€
ãªã³ã®å¹æ çŽæ¥çµåã€ãŒã©ã€ã¶æ³ãçšããŠãæäœâæåé¯
äœã®è§£é¢ã«å¯ŸããCa++ãMg++ããã³Mn++ã®å¹
æãæ€èšãããããããã³ãã³ãå«ãã€ã ãã³
ïŒImmulonïŒãã¬ãŒããTBSã§ïŒåæŽæµãã
åŸã23âã§ïŒïŒ BSAïŒTBSïŒïŒããªã¢ã«EDTA
ã§30åéæŽæµãããã±ã¬ãã¯ã¹ïŒChelexïŒ100
ããã€ãªã©ããïŒBioRadïŒããå«ãã«ã©ã ãçšã
ãŠéå±ãé€ããŠããŸã€ãæ°ŽãçšããŠäœæãã
TBSã§åŸ¹åºçã«æŽæµããããšã«ãã€ãŠãEDTA
ãšæ··å ¥ããŠããéå±ãåããé€å»ããã粟補ãã
ãç¹å¥ãªæäœãã0.1ã¢ã« ã°ãªã·ã³ãPH2.5ã§æº¶
åºãããæ¢å®ã®æ¡ä»¶äžã§ãJO1âïŒæäœã®ç·ãŠã
çµç¹å¹é€ç©äžæž 液ããé€å»ãããã çµæã¯ãCa++æ¿åºŠãå¢å ãããšãæäœâæå
çžäºäœçšãæžå°ããããã«ãªãããšã瀺ããã
0.9ããªã¢ã«CaCl2ã§ãåæ倧çµåã芳枬ãããã
å¯Ÿç §çã«ãïŒããªã¢ã«MnCl2ã§åæ倧çµåã芳枬
ããããé«æ¿åºŠã®Mg++ã¯ãæäœâæåå€äœã«é
å®çãªå¹æãæããã æäœâããããã³ãã³çžäºäœçšã«å¯Ÿããã«ã«ã·ãŠ
ã ã€ãªã³ã®å¹æ ïŒããªã¢ã«CaCl2ã®ååšãŸãã¯äžåšã«ãããã
çµç¹å¹é€ç©äžæž 液äžã®JO1âïŒæäœãšããããã³
ãã³ããã³ç°åžžããããã³ãã³ãšã®çžäºäœçšãã
åºçžãµã³ããŠã€ããã€ãŒã©ã€ã¶æ³ãçšããŠè©äŸ¡ã
ããJO1âïŒæäœã¯ãã«ã«ã·ãŠã ã€ãªã³ã®ååšãŸ
ãã¯äžåšã«ãããŠãç°åžžããããã³ãã³ã«çµåã
ãããγâã«ã«ããã·ã°ã«ã¿ãã³é žãæ¬ ããç°åžž
ããããã³ãã³ã¯ãéå±çµåæ§ãæãªãããŠããŸ
ã€ãŠãããéå±ã«ãã€ãŠèªèµ·ãããæ§é ç©é·ç§»ã
è¡ããªããå¯Ÿç §çã«ãJO1âïŒæäœã¯ãEDTAã®
ååšã«ãããŠã®ã¿ããããã³ãã³ã«çµåãããïŒ
ããªã¢ã«ã®CaCl2ã®ååšã§ã¯ãæäœã®ããããã³
ãã³ãžã®çµåã¯èŠãããªãã€ãããããã®çµæ
ã¯ãç°åžžããããã³ãã³ã«ç¹ç°çãªãã®ã¢ãã¯ã
ãã«æäœãããããã³ãã³ã®ç¡ã«ã«ã·ãŠã ã³ã³ã
ãªãŒããŒã«å¯ŸããŠã³ã³ããªã¡ãŒã·ãšã³ç¹ç°æ§ã§ã
ããããšã瀺ããã ããããã³ãã³ã«å¯Ÿããæåæ§æ±ºå®åº JO1âïŒæäœãšåºçžã«çµåããç°åžžããããã³
ãã³ãšã®çžäºäœçšãæå¶ããããããã³ãã³ãã
ã³ããããã³ãã³ã®ããªãããããã©ã°ã¡ã³ãã®
èœåãã競åã€ãŒã©ã€ã¶ïŒELISAïŒæ³ãçšããŠ
è©äŸ¡ãããïŒããªã¢ã«EDTAã®ååšã§ã¯ãç°åžž
ããããã³ãã³ãã©ã°ã¡ã³ãïŒïŒâ39ïŒãã©ã°ã¡
ã³ãïŒããã³ããããã³ãã³ã¯ãJO1âïŒæäœã«
å¹æçã«çµåãããå®éšèª€å·®ã®ç¯å²å ã§ãJO1â
ïŒæäœã¯ããããã®ããªããããäžã«çŸããæå
æ§æ±ºå®åºã«åœéçã«çµåããããã«æããããå
察ã«ã15ããªã¢ã«ã®CaCl2ã®ååšã«ããããã¹â
ïŒïŒâ44ïŒããããã³ãã³ã¯ãæäœã«çµåããªã
ã€ãããããã®çµæã¯ãããããã³ãã³ããã³ç°
åžžããããã³ãã³äžã§JO1âïŒæäœãåããããŠ
ããæåæ§æ±ºå®åºãããããã³ãã³ã®NH2âæ«
æºïŒâ39ã¢ããé žæ®åºå ã«å«ãŸãããã©ã°ã¡ã³ã
ïŒïŒâ39ïŒäžã«å®å šã«è¡šãããã åçºæ§è现èçãæ€åºããããã®ç°åžžããããã³
ãã³ã«å¯Ÿããæäœã®äœ¿çš äžè¿°ã®ããã«ãããç°åžžããããã³ãã³ã«åå¿
ãäžã€åããããããã³ãã³ãšã¯æ®ãã©åå¿ããª
ãïŒããªã¯ããã«ãŸãã¯ã¢ãã¯ããã«ïŒæäœã¯ã
ããæ£è ã®è¡æ¶²ãŸãã¯ä»ã®çç©åŠçè©Šæã«ããã
ç°åžžããããã³ãã³ã®ååšãæ€åºããããå ç«å
å®æ³ã«çšããããšãã§ãããŸãç°åžžããããã³ã
ã³ã®æ€åºã«ãã€ãŠãèæ©èœäžå šã®éæãè¡ãããš
ãã§ãããæ¬åºé¡äººçã¯ãçæåŠçè©Šæäžã®ç°åžž
ããããã³ãã³ãå®éããããšã«ãã€ãŠãåçºæ§
è现èçã®èšºæãè¡ãããšãã§ããããšãèŠãåº
ããã åçºæ§è现èçã¯ãαâããšãã¿ã³ãã¯è³ªãç°
åžžãã¿ãã³B12çµåå€ããšãªããããšãã³ããã³
ç°åžžãã€ããªããŒã²ã³ã®ãããªè¿·èµ°æ§ããã³ç°æ
æ§ã¿ã³ãã¯è³ªã®åæã«é¢é£ããŠããããšãç¥ãã
ãŠããè «çã§ããããã®ãã®ã¿ã³ãã¯è³ªã®å¹Ÿã€ã
ã¯ãç¹ã«Î±âããšãã¿ã³ãã¯è³ªã¯ãåŠçããã³ç®¡
çãé©åã«ããäžã§æ©æã®äžã€æ£ç¢ºãªèšºæãéèŠ
ãªç æ°ã®èšºæããŒã«ãŒãšããŠäœ¿çšãããŠãããé«
ã¬ãã«ã®ç°åžžããããã³ãã³ã®ååšã¯ã次ã«è©³çŽ°
ã«èª¬æããããã«ãæãç¹ã§ã¯äžèšã¿ã³ãã¯è³ªã®
æããã®ãããããããåçºæ§è现èç蚺æããŒ
ã«ãŒã§ããã çæ€ã«ãã€ãŠè现èçã§ããããšã確ãããã
ã40人ã®å°æ¹Ÿäººæ£è ãš26人ã®ç±³åœäººæ£è ã«ã€ããŠ
æ€èšãããæ²»çåã«ããããã®æ£è ããè¡æž è©Šæ
ãæ¡åãããçæ€ã§ïŒ¢åè¡šé¢æåéœæ§ã®æ ¢æ§æŽ»å
æ§èçãšèšºæããã28人ã®æ£è ããã³17人ã®èè
ãå«ã転移æ§çæ£è ã«ã€ããŠãæ€èšãããè现è
çæ£è ã®å¹³å幎什ã¯ã54æã§ãã€ãã€ããããã
ã®æ£è ã®64ïŒ ã¯ãåèçè¡šé¢æäœã«éœæ§ã§ãã€
ããåèçææã®ä»ã®è¡æž ããŒã«ãŒïŒïŒ¢åèç
è¡šé¢æäœãèçã³ã¢æäœãBeåèçæåããã³
BeåèçæäœïŒãå°æ¹Ÿäººæ£è ã«ã€ããŠæž¬å®ãã
ãšããã50人äž41人ïŒ82ïŒ ïŒãåèçã«ææã
ãŠããããšãæããã«ãªã€ãã åããããã³ãã³ããã³ç°åžžããããã³ãã³
ããäžè¿°ã®ç«¶åçæŸå°å ç«åå®æ³ã§ããªã¯ããã«
æäœãçšããŠæ£è ã®è¡æž ã§æž¬å®ãããåå®éã®å€
åã¯ã10ïŒ ä»¥äžã§ãã€ããαâããšãã¿ã³ãã¯è³ª
æåããã³ïŒ¢åèçè¡šé¢æåãã競åçæŸå°å ç«
åå®æ³ïŒÎ±âããšãâRIAãããïŒïœâFetoâ
RIAKitïŒããã€ããããïŒDainabotïŒãæ±äº¬ãã
ãã³ã¢ãŠã¹ãªã¢ãããïŒAUSRIA KitïŒãã¢ãã
ã ã©ãã©ããªãŒãºïŒAbbott LaboratoriesïŒã·
ã«ãŽãã«ãã€ãŠè¡æž äžã§æž¬å®ãããããããã³ã
ã³æéãæšæºæ³ã«ãã€ãŠã¯ãšã³é žå¡©å è¡æŒ¿äžã§æž¬
å®ãããããŒã¿ããŸãšããŠãã¯ãªã³ããª
ïŒCLINFOïŒã·ã¹ãã ïŒããã¯ã¹ïŒVAXïŒ
ïŒ730ã³ã³ããŠã¿ãŒïŒã«ãã€ãŠåæããã ç°åžžããããã³ãã³ã«å¯Ÿããå€ã¯ãæ£èŠååžã«
åŸããªãã€ãã®ã§ãçµ±èšåæã«å¹Ÿäœå¹³åã®èšç®ã
åãå ¥ããã 76人ã®è现èçæ£è ã«ãããç°åžžããããã³ã
ã³æåããã³åããããã³ãã³æåã®ååžãã第
ïŒå³ã«ç€ºãïŒç°åžžããããã³ãã³ã®å€§ããã¯ïŒæ¡
ã«äºã€ãŠå€åããã®ã§ã察æ°ç®çãã§ç€ºããŠã
ãïŒããããã®æ£è ã®91ïŒ ïŒ76人äž69人ïŒã«ãç°
åžžããããã³ãã³ãæ€åºããããç·ãŠã®æ£è ã§ã®
å¹³åã¯ã900nïœïŒmlïŒç¯å²ãïŒâ67.000ïŒã§ãã€
ããç°åžžããããã³ãã³æåãšåããããã³ãã³
æåãšã®éã«ã¯ãçžé¢ã¯ãªãã€ããåããããã³
ãã³æåã®å¹³åå€ã¯ã90000±28000nïœïŒmlã§ã
ããããã¯æ£åžžè¢«éšè ã«ã€ããŠæž¬å®ããå€
ïŒ108000±19000nïœïŒmlïŒïŒïœâ0.34ãã¹ããŠãŒã
ã³ãã®ïœâæ€å®ïŒãšææå·®ã¯ãªãã€ãã è现èçæ£è ã¯ãäžè¿°ã®ããã«ãã¿ãã³ïŒ«æ¬ ä¹
çæ£è ãåããããã³ãã³æåã®å€ãäœãã®ã«æ¯
ã¹ãŠãæ£åžžã®åããããã³ãã³æåã®å€ãæã
ããããããã³ãã³æéææšãããã¿ãã³ïŒ«æ¬ ä¹
æ£è ã§ã¯äœäžããã®ã«ã66人ã®æ£è äž46人ãæ£åžž
ã§ãã€ãã ãããã®æ£è ã§ã®ç°åžžããããã³ãã³ã®äžæã
æœåšçãã¿ãã³ïŒ«æ¬ ä¹çãåæ ããŠãããšããå¯
èœæ§ãé€ããããïŒäººã®æ£è ã«ãã¿ãã³ïŒ«ïŒ20mgïŒ
ãé£ç¶ïŒæ¥ééçµå£çã«åå²æäžããïŒæ¥éç°åžž
ããããã³ãã³æåã®å€ã枬å®ãããã¿ãã³ïŒ«æ¬
ä¹çïŒäººã®æ£è ã®å€ïŒç¬¬ïŒè¡šïŒãšæ¯èŒãããè¡æž
ç°åžžããããã³ãã³æåã®å€ã¯ããããŒãæ£è ã§
ã¯ææã«ã¯å€åããªãã€ããããã¿ãã³ïŒ«æ¬ ä¹æ£
è ã§ã¯äºæããããã«æžå°ããã
ããã«è¡æ¶²ååºã®æçµæ®µéã«é¢äžãããã¿ãã³ïŒ«
äŸåæ§è¡æŒ¿èçœè³ªã§ãããããã¯çŽ72000ã®åå
éããã¡ãçŽ12ïŒ ã®çæ°Žåç©ãå«æãããããã
ãã³ãã³ã¯æ¢ç¥ã®ãšããã«ã«ã·ãŠã ã®ååšäžã§ç«
äœé 座ãå€åããã«ã«ã·ãŠã çµåæ§èçœè³ªã§ã
ããããããã³ãã³ããããã³ãã³ãžã®èçœå解
ã䌎ã掻æ§åã¯æ£åžžãªæ¢è¡ã«ãããéèŠãªå·¥çšã§
ãããããããã³ãã³ã¯èèã§åæãããããã
ã§ããããã³ãã³åé§ç©è³ªã翻蚳åŸä¿®é£Ÿãåã
ãŠãããããã³ãã³ã®æ©èœåœ¢ã«ãªããããã¯â倩
ç¶ããããã³ãã³âãšããŠç¥ãããγâã«ã«ãã
ã·ã°ã«ã¿ãã³é žãå«æããããã¿ãã³ïŒ«æ®æè¬ã
ããšãã°ã¯ã«ãã¢ãªã³ãããªãŠã ïŒãã©ãŠãšã¢å·
ãŠã€ã«ãã³ãã³ã®ããŠãã³ç€Ÿãšã³ãã»ã©ãã©ããª
ãŒãºéšéã®åæšã¯ããžã³ïŒCoumadinïŒãæãã
補åãšããŠãç¥ãããŠããïŒã®ååšäžã§ããŸãã¯
ãã¿ãã³ïŒ«ã®äžåšäžã§ãè¡äžã®ããããã³ãã³æŽ»
æ§ã¯ææã«äœäžããå¯èœæ§ããããããã¯ããã
ãã³ãã³æéïŒäžæ®µåè¡ã¢ãã»ã€æ³ïŒã«ããéæ¥
çã«ããŸãã¯ããããã³ãã³æ¬ æåºè³ªè¡æŒ¿ãçšã
ãããããã³ãã³åè¡æŽ»æ§ã®çŽæ¥æž¬å®ã«ãã枬å®
ããããšãã§ãããè¡æŒ¿ããããã³ãã³æŽ»æ§ãäœ
ãå Žåãéçã®èçŸæ£ã䌎ãå¯èœæ§ããããããš
ãã°èçœè³ªåæé害ïŒèçŸæ£ïŒãäžé©åœãªãã¿ã
ã³ïŒ«äŸçµŠïŒãã¿ãã³ïŒ«æ¬ ä¹çïŒããŸãã¯ãã¿ãã³
ã®äœçšãææ¢ããè¬ç©ïŒã¯ã«ãã¢ãªã³ãããªãŠ
ã ïŒã¯ãããã®ä»ã®åºä¹³é¡ã«ãããè¡æŒ¿ãããã
ã³ãã³æŽ»æ§ãäœäžãããã ã¯ããžã³ã¯ã¯ã«ãã¢ãªã³ã®åååã§ãããã¯ã
ãžã³ãè¡æ æ§çŸæ£ã®æ²»çãŸãã¯äºé²ã«éãåºãè¡
ãããŠããããã«çµå£æåè¡è¬ãšããŠçšãããšã
ããã¯ãã¿ãã³ïŒ«äŸåæ§è¡æ¶²ååºèçœè³ªãããšã
ã°ããããã³ãã³ã®æŽ»æ§ãäœäžããããé©åãªã¯
ããžã³çšéã¯ããããã³ãã³æéã®ç£èŠã«ãã確
ç«ããããããããã³ãã³æéã¯æ£åžžãªè¡æŒ¿ã«é¢
ããŠåŸãããæéã®ïŒ1/2ãïŒïŒ1/2åã«ç¶æãã
ãã 1968幎ã«ãã¯ã«ãã¢ãªã³ãããªãŠã ã§æ²»çãã
æ£è ã®è¡æŒ¿äžã«ããã倩ç¶ããããã³ãã³ã«å¯Ÿæ¯
ããŠâç°åžžããããã³ãã³âããã³âããç°åžžã
ãããã³ãã³âãšããŠç¥ãããããããã³ãã³ã®
å€åœ¢ãçºèŠããããç°åžžããããã³ãã³ããã€ã
ãããã³ãã³æŽ»æ§ã¯äœãããå€æ°ã®ããããã³ã
ã³æè¡æž ãšäº€ååå¿ããããŠã·è¡æ¶²ããç°åžžãã
ããã³ãã³ã1972幎ã«åããŠåé¢ãããããã®çš®
ã®ç°åžžããããã³ãã³ã¯çéã®å€©ç¶ããããã³ã
ã³ã®çŽïŒïŒ ã®åè¡æŽ»æ§ããã€ããšãèªããããã
ãã®ã»ãååéãé žå æ°Žå解ã®çæ°Žåç©çµæãã
ã³ã¢ããé žçµæã¯å®è³ªçã«å®éšèª€å·®ã®ç¯å²å ã§ç
ããã€ãã1970幎代åæã«ãŠã·ç°åžžããããã³ã
ã³ã¯ããããã³ãã³ãšç°ãªãããªãŠã å¡©ã«çµåã
ããã«ã«ã·ãŠã ã€ãªã³ã«çµåããªãããšãèŠåºã
ããããã®åŸãç°åžžããããã³ãã³ãšå€©ç¶ããã
ãã³ãã³ãšã®æ©èœäžã®çžéã¯ãããã®èçœè³ªéã®
æ§é äžã®çžéã«é¢ä¿ããããå®å šãªããããã³ã
ã³æ©èœã«ã¯ç¡å·ã®ã«ã«ã·ãŠçµåéšäœãå¿ èŠãšãã
ããšã瀺ãããã1970幎代äžæã«ããããŸã§ç¥ã
ããŠããªãã€ãã¢ããé žã§ããγâã«ã«ããã·ã°
ã«ã¿ãã³é žããŠã·ããããã³ãã³äžã«ååšããã
ããç°åžžãŠã·ããããã³ãã³ã«ã¯æ¬ åŠããŠããã
ãšãèŠåºãããããã®ã¢ããé žã¯ããããã³ãã³
ã®åè¡æŽ»æ§ãå®å šã«çºçŸããããã«å¿ èŠã§ãããš
æããããç°åžžããããã³ãã³ã¯åè¡æŽ»æ§ããã
ãªãããšãç¥ãããŠãããéå±ã€ãªã³ãçµåã
ããγâã«ã«ããã·ã°ã«ã¿ãã³é žãå«ãŸãªããä»
ã®ç 究è ãã¯ãããããã³ãã³ãèèå ã§Î³âã«
ã«ããã·ã°ã«ã¿ãã³é žã®ä»£ããã«ã°ã«ã¿ãã³é žã
å«æããåé§ç©è³ªã®åœ¢ã§åæãããããšçè«ã¥ã
ããèèå ã§ã®ã«ã«ããã·ã«åéçšã§ã°ã«ã¿ãã³
é žã修食ãããŠÎ³âã«ã«ããã·ã°ã«ã¿ãã³é žã圢
æãããããã®é µçŽ ç³»ã¯ãã¿ãã³ïŒ«ãå¿ èŠãšãã
ãã¿ãã³ïŒ«æ®æè¬ã«ããæå¶ãããã äœæ¶²ãããšãã°è¡æŒ¿äžã®ããããã³ãã³ããã³
ç°åžžããããã³ãã³ã®æ°Žæºã枬å®ããããã®å®é
çã¢ãã»ã€æ³ãéçºããããã«ããããŸã§å€ãã®
åªåããªãããŠããããããã®æ¹æ³ã«ã¯ãããŸã§
èããå¶éããã€ããããç°åžžããããã³ãã³ã
ãã³ãã倩ç¶ããããã³ãã³ã¯å ±ã«584åã®ã¢ã
ãé žãå«ã¿ããããã®ãã¡574åã¯ãããïŒåœ¢æ
ã«ãããŠçãããæ®ãã®10åã¯ã«ã«ããã·ã«åºã«
ãããŠç°ãªãã«ãããªããšããç¹ã§ãã¢ãã»ã€æ³
ãèæ¡ããããšã¯å°é£ã§ãã€ãããããã®èçœè³ª
ã¯ãæ§é äžã¯ã»ãŒçãããæ©èœçé¢äžã«ãããŠã¯
ããããŠç°ãªã€ãŠãããè¡æ¶²ååºã«é¢ããŠç°ãªã
圹å²ããã€ã è¡æ¶²ååºã®å€å æ§çµè·¯ã«ãããããããã³ãã³
ããã³ä»ã®èçœè³ªãè©äŸ¡ããããã®æ¢åã®æ¹æ³ã«
ã¯ãäžè¬çãªããããã³ãã³æé枬å®æ³ãå«ãŸã
ããããã¯ç°åžžããããã³ãã³æ°Žæºãæ€åºããã
ã®ã§ã¯ãªããããããã³ãã³ã®åè¡æŽ»æ§ã®çŽæ¥ã¢
ãã»ã€ã¯ã被éšè¡æŒ¿ãçš®ã ã®å²åã®ããããã³ã
ã³æ¬ æè¡æŒ¿ãšæ··åãã次ãã§åè¡ãããæšæºæ²ç·
ãšæ¯èŒããããšã«ããè¡ãããã倩ç¶åã®æ©èœæ§
ããããã³ãã³ã®ã¿ã枬å®ãããã亀åå ç«é»æ°
æ³³åæ³ã¯ç°åžžããããã³ãã³ããã³å€©ç¶ãããã
ã³ãã³ã®åæ¹ãæºå®éçã«æž¬å®ããããäŸäžçš®ã
ä»æ¹ãé èœããã®ãé²ãããã«ã¯åæ§ãªæ¿åºŠã§ã
ãããšãå¿ èŠã§ãããåŸã€ãŠçšéãéå®ãããã
ä»ã®å é£ãªãã€æè¡ãèŠããè©Šéšæ³ã¯ããŒã¬ã«
ïŒLaurellïŒã®ãã±ããå ç«é»æ°æ³³åæ³ã§ãããã
ãã¯äžèšïŒçš®ã®ããããã³ãã³ãåºå¥ã§ããªãã
ããããã³ãã³ã®ã©ãžãªã€ã ãã¢ãã»ã€ãè¡ãã
ããããããŸã§ã«çšããããæäœã¯ç°åžžãããã
ã³ãã³ã«ãæ£åžžããããã³ãã³ã«ãåçã«ïŒãŸã
ã¯ã»ãšãã©åçã«ïŒçµåããåŸã€ãŠç·ããããã³
ãã³æ°Žæºã枬å®ãããã«ããããèšåºèšºæçšãšã
ãŠã¯äžååã§ãããèæ¯ãçšãããšãã¹ã»ã«ãªã
ãŒã¿ã¹ïŒæ¯èã®äžçš®ãEchis carinatusïŒã¢ãã»
ã€æ³ã¯ç·ããããã³ãã³ã®æž¬å®ã«çšãããããäº
段ããããã³ãã³ã¢ãã»ã€æ³ãšçµåããŠãããã®
ã¢ãã»ã€ãéæ¥çã«ç°åžžããããã³ãã³æ°Žæºã®æš
å®ã«çšããããšãã§ããã äžèšã¢ãã»ã€æ³ã®ãããããç¹ã«ããã«ãããŠ
ç°åžžããããã³ãã³ã®ååšäžã§ã®ããããã³ã
ã³ããããã¯æ£åžžããããã³ãã³ã®ååšäžã§ã®ç°
åžžããããã³ãã³ã«é¢ããçŽæ¥çãå®éçãªã容
æã«å®æœãããæ床ã®é«ãç¹ç°çã¢ãã»ã€æ³ãæ
äŸããªããæ¬çºæã«ãããŠã¯èçœè³ªè¡šé¢ã®ç¹å®é
åã«å¯Ÿããç«äœé 座ç¹ç°æ§æäœãçšããç 究ãè¡
ãããã®çµæç°åžžããããã³ãã³ã«å¯ŸããŠããã
ã³å€©ç¶ããããã³ãã³ã«å¯ŸããŠç¹ç°çãªå ç«ååŠ
çè©Šè¬ãéçºããããç°åžžããããã³ãã³ããã³
倩ç¶ããããã³ãã³ã被éšåºä¹³åç©ããåŸããã
è¡æž æ€äœã®ãã®ã§ããæ¹æ³ãèšè¿°ãããããã«ã
ãåºä¹³åç©è¡æŒ¿äžã®ç°åžžããããã³ãã³ãŸãã¯å€©
ç¶ããããã³ãã³ã®æ°Žæºã枬å®ãããããã«ãã
ãŠã¯ç°åžžããããã³ãã³ã®ååšã¯èº«äœã®é害ã瀺
ãã奜ãŸãã圢æ ã«ãããŠã¯ãããã®ç°åžžããã
ãã³ãã³ããã³æ£åžžããããã³ãã³ã®æž¬å®ã¯ä»æ¹
ã®ååšäžã§ããããã«å¯Ÿãç¹ç°çãªæäœã®äœ¿çšã«
ãã€ãŠè¡ãããã身äœã®é害ããã¿ãã³ïŒ«æ¬ ä¹ç
ã§ããå Žåãç°åžžããããã³ãã³ã®æ°Žæºãç£èŠã
ãããããããå®ããããæ°Žæºã«ç¶æãããã奜
ãŸããã¯æåè¡è¬ã®æäžãããšãã°ã¯ã«ãã¢ãªã³
ã®æäžãèŠæ±ãããå Žåãæäžããã¯ã«ãã¢ãªã³
ã®ç®çæ°Žæºãªããã¯ç®çéãæ瀺ãããã®ãšããŠ
倩ç¶ããããã³ãã³ãç£èŠããã倩ç¶ããããã³
ãã³ã®æ°Žæºããã®æ¹æ³ã§å®éçã«æž¬å®ããããšã
ã§ãããããã®ãã¿ãã³ïŒ«æ®æè¬ïŒããšãã°ã¯ã«
ãã¢ãªã³ïŒã«ããæåè¡çæ³æéäžããããã®æ°Ž
æºãå®éçã«æž¬å®ããã®ã¡12ã24ÎŒïœïŒmlã®å€©ç¶
ããããã³ãã³æ°Žæºãã䜿çšäžã®è¬ç©ïŒããšãã°
ã¯ã«ãã¢ãªã³ãããªãŠã ïŒãããã«æäžããããš
ã«ããç¶æãããã奜ãŸããã¯å€©ç¶ããããã³ã
ã³ã¯10ã24ÎŒïœïŒmlã®äœæ¶²å æ°Žæºã«ç¶æãããã æ¬çºæã«ããã°ãã倩ç¶ããããã³ãã³ããã³
ã«ã«ã·ãŠã ã®ååšäžãã¹âγâã«ã«ããã·ãã
ïŒããªãã¡ç°åžžïŒããããã³ãã³ãšåå¿æ§ã§ããã
ã«ã«ã·ãŠã ã€ãªã³ã®ååšäžã§ãã倩ç¶ããããã³
ãã³ãšã¯å®è³ªçã«éåå¿æ§ã§ããã¢ãã¯ãâãã«
æäœãæäŸãããã ç°åžžããããããã³ãã³ã«å¯Ÿããããªã¯ããŒã
ã«æäœãšç°ãªãæ¬çºæã®ã¢ãã¯ããŒãã«æäœã¯ã«
ã«ã·ãŠã ã€ãªã³ã®äžåšäžã§ãã倩ç¶ããããã³ã
ã³ãšè€åäœã圢æãããå©ç¹ããã€ãæ¬çºæã®ã¢
ãã¯ããŒãã«æäœã¯ãã€ã³ãããè©Šéšçšäœæ¶²äžã§
æšæºçãªå®éšå®€æ¡ä»¶äžãããšãã°å®€æž©ãæšæºç倧
æ°å§ãããã³ãããã®æ®éã®å€åã«ãããŠåå¿æ§
ã§ãããè€åäœã圢æããç¹ã§å¥œãŸããã å®éçããã³å®æ§ç枬å®å€ãåŸãããã®ã€ã ã
ã¢ãã»ã€ãè¡ãæ¹æ³ã«ãããŠã¯ãäžè¬çãªã€ã ã
ã¢ãã»ã€æäœæ³ãæ¡çšããããšãã§ããããã«ã¯
é µçŽ çµåã¢ãã»ã€æ³ããã³ã©ãžãªã€ã ãã¢ãã»ã€
æ³ãå«ãŸããã ããç°åžžããããã³ãã³ã®ååŠã¯ãè¡æŒ¿ãŸãã¯
è¡æž è©Šæã«ã€ããŠåèšã®é©å®ãªã¢ãã¯ããŒãã«æ
äœãšã®å ç«åå¿ãè¡ãªãããããŠæäœâæåè€å
äœã®ååŠãåžžæ³ã«ããå®æ§çãŸãã¯å®éçã«æž¬å®
ããããšã«ãã€ãŠæž¬å®ãããã 人äœå ã«ãããããç°åžžããããã³ãã³ã®ååš
ã¯ãèçŸæ£ç¶æ ã«ããå Žåãåäœããã¿ãã³ïŒ«æ®
æè¬ãªã©ã®ç©è³ªã§åŠçããå Žåããã¿ãã³ïŒ«æ¬ ä¹
ã®å ŽåããŸãã¯ã«ã«ããã·ã«åé害ããããã代
è¬æ¬ é¥ã®çµæ以å€ã¯ãè¡æŒ¿ãè¡æž ãŸãã¯ä»ã®äœæ¶²
ïŒmlåœãã0.03ÎŒïœãè¶ããããšã¯ãªããå®éã«
ã¯æ¶²äœïŒmlåœãã0.03ÎŒïœä»¥äžã®æ°Žæºããã®çš®ã®
çŸæ£ã瀺ããã®ãšèãããããããã®ããã«äœã
æ°Žæºãæ¬çºææ¹æ³ã«ããæ¢ç¥ããããšã¯ã§ããª
ããç°åžžããããã³ãã³ã®ååšã¯ããããäžèšã®
çŸæ£ããã³é害ã瀺åãããã®ãšèãããããåŸ
ã€ãŠã€ã ãã¢ãã»ã€æ³ãçšããŠç¹å®ã®èçŸæ£ã®å
åŠãå€å®ããèçŸæ£ãç°åžžããããã³ãã³ãæ£åžž
ãªç¶æ ããå€åããŠããç¹å®ã®ä»ã®èº«äœæ©èœäžå š
ãšåºå¥ãããŸãæ£è ã«æäžããã¯ã«ãã¢ãªã³ãã
ãªãŠã ã®éã決å®ããŠè¡æ çãŸãã¯åºè¡ã®å±éºæ§
ãæå°éã«æããããšãã§ããã 第ïŒå³ã¯ãæ°çš®ã®å»åŠçé害ã䌎ãæ£è ã«ãã
ã倩ç¶ããããã³ãã³ããã³ç°åžžããããã³ãã³
ã®è¡æž æ¿åºŠã瀺ãã°ã©ãã§ããã 第ïŒå³ã¯ããã¿ãã³ïŒ«æ¬ ä¹çã䌎ãæ£è ã«ãã
ãŠãã¿ãã³ïŒ«çæ³ã倩ç¶ããããã³ãã³ããã³ç°
åžžããããã³ãã³ã«äžãã圱é¿ã瀺ãã°ã©ãã§ã
ãã 第ïŒå³ã¯ãè现èæ§çã䌎ãæ£è ã«ãããç°åžž
ããããã³ãã³ããã³å€©ç¶ããããã³ãã³ã®è¡æž
æ¿åºŠã瀺ãã°ã©ãã§ããã 第ïŒå³ã¯ãèçæ£è ïŒäººã«ãããç°åžžãããã
ã³ãã³ããã³Î±âããšããããã€ã³ã®è¡æž æ¿åºŠã
瀺ãã°ã©ãã§ããã 第ïŒå³ã¯ãïŒçš®ã®ç°ãªãèèé害ã䌎ãåæ£è
ã«ãããç°åžžããããã³ãã³ã®è¡æž æ¿åºŠã瀺ãã°
ã©ãã§ããã 第ïŒå³ã¯ãèçæ£è ã«ãããç°åžžããããã³ã
ã³ããã³Î±âããšããããã€ã³ã®è¡æž æ¿åºŠã瀺ã
ã°ã©ãã§ããã 第ïŒå³ã¯ãåçš®ã®å»åŠçé害ã䌎ãåæ£è ã®è¡
æž äžã«ãããç°åžžããããã³ãã³æ°Žæºã瀺ãã°ã©
ãã§ããã ããããã³ãã³çåæé害ã®æ€åºããã³èšºæã¯
ããã«ãããŠè¡æŒ¿ãŸãã¯è¡æž ã®ç°åžžããããã³ã
ã³ã®æž¬å®ã«ããè¡ãããšãã§ãããç°åžžãããã
ã³ãã³ã®ç¹ç°çã¢ãã»ã€ãããè¡æŒ¿ãŸãã¯è¡æž ã«
ãããŠæ¡çšããããããã³ãã³çåæã®ç¶æ ãå€
å®ããããã®æ å ±ã¯ç¹å®ã®çŸæ£ã®ç¶æ ãšãçžé¢ã
ãŠããå¯èœæ§ãããã çåžžè¡æŒ¿ïŒæ£åžžãªåäœããåŸãããè¡æŒ¿ããã³
è¡æž ã¯æ€åºå¯èœãªç°åžžããããã³ãã³ãå«ãŸãª
ãããã®ã¢ãã»ã€æ³ã®æ床ããã³ç¹ç°æ§ã¯ãç°åžž
ããããã³ãã³ã0.03ÎŒïœïŒml以äžãšãªãåŸãªã
ããšã瀺ããŠãããæ£åžžæ°Žæºã®å€©ç¶ããããã³ã
ã³ã¯çŽ108ÎŒïœïŒmlã§ããã æ¥æ§èçïŒæ¥æ§èçã䌎ãæ£è ããåŸãè¡æŒ¿ã
ãã³è¡æž ã¯0.1ã6ÎŒïœïŒmlãŸãã¯ãã以äžã«å€å
ãã倧éã®ç°åžžããããã³ãã³ãå«æããã倩ç¶
ããããã³ãã³ã®æ°Žæºã¯éåžžã¯æ£åžžã§ããããæ£
åžžãªããããã³ãã³ã®ç¯å²ãããé«ããŸãã¯äœã
ãªãå¯èœæ§ãããã 硬å€ïŒã¢ã«ã³ãŒã«è硬å€ã䌎ãæ£è ããåŸãè¡
挿ããã³è¡æž ã¯é«ãç°åžžããããã³ãã³ãå«ãã
ããããã³ãã³æ°Žæºã¯éåžžã¯æºæ£åžžã§ããã æ ¢æ§æŽ»åæ§èçïŒæ ¢æ§æŽ»åæ§èçã䌎ãæ£è ã
ãåŸãè¡æŒ¿ããã³è¡æž ã¯æ€åºå¯èœãªç°åžžãããã
ã³ãã³ãå«ãŸãªãã ãã¿ãã³ïŒ«æ¬ ä¹çïŒè žã«ããããã¿ãã³ïŒ«åžå
äžå šãè žè埪ç°é害ãæ é€æ¬ ä¹ããŸãã¯ææ§ç©è³ª
ã«ããè žå 现èã®åŠšå®³ã«åºã¥ããã¿ãã³ïŒ«æ¬ ä¹ç
ã¯ç°åžžããããã³ãã³ããã³ããã«çžåœãããã
ããã³ãã³äœäžã䌎ãããããã®æ£è ã¯ãã¿ãã³
ã«å¿çããã èèãå«ã転移æ§çïŒèèã®ç Žå£ãå«ãçã䌎
ãæ£è ã«ãããŠã¯ç°åžžããããã³ãã³æ°Žæºãé«
ãã è现èæ§çïŒç°åžžããããã³ãã³ãäžæ§ã«ååš
ãããæ°Žæºã¯äœãæ°ŽæºããããããŠé«ãæ°Žæºã«ãŸ
ã§å€åããã倩ç¶ããããã³ãã³ã®æ°Žæºã¯æ£åžžã§
ããããå€åããããã 蚺æã®è£äœã«ã¯äžèšã®ãã®ãå«ãŸããã (a) ç°åžžèæ©èœç 究ã«ããããããã³ãã³æéã®
延é·ã䌎ãæ£è ã¯ãèçŸæ£ãŸãã¯ãã¿ãã³ïŒ«æ¬
ä¹çãæããå¯èœæ§ããããé«æ°Žæºã®ç°åžžãã
ããã³ãã³ããã³äžçšåºŠã«äœãæ°Žæºã®ãããã
ã³ãã³ã¯ãã¿ãã³ïŒ«æ¬ ä¹çã瀺åãããäœãæ°Ž
æºã®ç°åžžããããã³ãã³ããã³æ£åžžãªæ°Žæºã®ã
ãããã³ãã³ã¯èçŸæ£ã瀺ãã (b) æ£è ã¯æ°åãæªããè¡æ¶²åŠçæ€æ»ããã³è ã¹
ã¯ãªãŒãã³ã°ãã¹ãã¯ãã¹ãŠæ£åžžã§ãããç°åžž
ããããã³ãã³æ°Žæºã®äžæã¯æœåšæ§èçŸæ£ã瀺
ãã (c) é»çžããã³èããåè¡é害ã䌎ãåºè¡æ§æ£è
ã¯ç°åžžããããã³ãã³ã®å¢å ã瀺ãããšãèªã
ããããããã¯èçŸæ£ã®èšºæã瀺ããã®ã§ã
ããè¡ç®¡å åè¡ã瀺ããã®ã§ã¯ãªãã (d) ããâæ£åžžãªâåäœãèããåºè¡ãçããã
ããããã³ãã³æéã延é·ããŠãããããããŠ
é«ãç°åžžããããã³ãã³ããã³äœãããããã³
ãã³ã¯ãã¯ã«ãã¢ãªã³ã®éå°æäžãããªãã¡äž
èªç¶ãªã¯ã«ãã¢ãªã³æåã瀺åããã (e) ïŒå¹Žåã«åçºæ§é»è²è «ã䌎ã€ãæ£è ãå šèº«å
ã®çç¶ãçºçŸããŠãããç°åžžããããã³ãã³ã®
å¢å ã¯çã®è浞最ã瀺åããã (f) ããæ£è ãåçºæ§è¡æ çã®æå¶ã®ããã¯ã«ã
ã¢ãªã³ã§æ²»çãããã倩ç¶ããããã³ãã³æé
ã¯æ²»çç¯å²ã«ããã«ããããããã倩ç¶ããã
ãã³ãã³ã¯36ÎŒïœïŒmlã§ãããšæž¬å®ããããã
ã®æ£è ã¯è¡æ çã®æãããããšèšºæããããã¯
ã«ãã¢ãªã³ã®ïŒæ¥éãé«ãã倩ç¶ããããã³ã
ã³ãå®æçã«ç£èŠããã ã¢ãã»ã€æ³ã«çšããããã®æ¬çºæã®æäœã®ãã€
ã¢ã«ãå«ãã€ã ãã¢ãã»ã€ããããçšæããããš
ãã§ãããããšãã°ããç°åžžããããã³ãã³ã«ç¹
ç°çãªæšèãããããŸãã¯æšèãããŠããªãæäœ
ã®ãã€ã¢ã«ãçšæããRIAãã®ä»ã®ã€ã ãã¢ãã»
ã€ãããã«çšããä»ã®ææãšå ±ã«å è£ ããããšã
ã§ããããã®çš®ã®ãããã«ãããææã®å®¹ç©ãã
ã³ãããã®æ§æéšåã®æ°ã¯å€§å¹ ã«å€ãããããã
ã®çš®ã®ãããã¯ãããã®æäœãšæåâæäœè€åäœ
ã圢æããæåã®ååŠããã³éã枬å®ããã€ã ã
ã¢ãã»ã€æ³ãå®æœããããã®æ瀺ãå ±ã«é åžãã
ãå Žåãå€ãã ãããã®å ç«ååŠç©è³ªãè©Šè¬ãšããŠçšããŠãã
ãè¡æŒ¿ãŸãã¯è¡æž äžã®ç°åžžããããã³ãã³ã«é¢ã
ãç¹ç°çã©ãžãªã€ã ãã¢ãã»ã€æ³ãéçºãããã
ãããã®ã©ãžãªã€ã ãã¢ãã»ã€æ³ã¯æšæºçãªäºé
æäœæ²æ®¿æ³ããã³æŸå°æ§ãšãŠçŽ åããæåã䌎
ããç°åžžããããã³ãã³ã«é¢ããã¢ãã»ã€æ³ã¯
2nïœïŒmlã«åã¶æ床ã瀺ããããããã³ãã³
150ÎŒïœã®ååšäžã§ã®ç°åžžããããã³ãã³æ€åºé
çã¯0.03ÎŒïœïŒmlã§ãããæ£åžžãªè¡æŒ¿ã¯ç°åžžãã
ããã³ãã³ãå«ãŸãªããäœæ°ŽæºïŒ0.2ã8ÎŒïœïŒmlïŒ
ã®ç°åžžããããã³ãã³ã¯çš®ã ã®èçŸæ£ã«ç¹åŸŽçã§
ããïŒèçã硬å€ã転移æ§æªæ§çãåçºæ§è现è
æ§çïŒã察å¿ããäœãããããã³ãã³ã䌎ãäœæ°Ž
æºãªããã¯é«æ°Žæºã®ç°åžžããããã³ãã³ïŒïŒã
100ÎŒïœïŒmlïŒã¯ãã¿ãã³ïŒ«æ¬ ä¹ã®çšåºŠãšé¢é£ã
ããã¯ã«ãã¢ãªã³ãããªãŠãæåããŠããæ£è ã¯
35ÎŒïœïŒmlã®ç¯å²ã®ç°åžžããããã³ãã³æ°Žæºãã
ãã³10ã30ÎŒïœïŒmlã®ããããã³ãã³æ°Žæºãã
ã€ããã®ç°åžžããããã³ãã³ããã³ããããã³ã
ã³ã®æž¬å®ã«ããããã¿ãã³ïŒ«äŸåæ§ã«ã«ããã·ã«
åã®é害ãç¹è²ãšããçŸæ£ã䌎ãæ£è ã確èªã
ïŒã¹ã¯ãªãŒãã³ã°ãïŒã蚺æããããšãã§ãããã
ããã®æž¬å®ãçµå£æåè¡è¬çæ³ã®ç£èŠããã³å¶åŸ¡
ã«çšããããšãã§ãããæåŸã«ããããçšããŠãŠ
ããããã³ãã³åæã®é害ãšããããã³ãã³ç°å
å éïŒã¯ãªã¢ã©ã³ã¹ã®é害ãåºå¥ããããšãã§ã
ãã è©Šéšã¯æ®éã¯è¡æž ãŸãã¯è¡æŒ¿äžã§è¡ããããã
ãããå šè¡äžã§è¡ã€ãŠçžåœããçµæãåŸãããšã
ã§ããã ã¯ã«ãã¢ãªã³ç£èŠã«ã€ããŠèšè¿°ããããä»ã®ã
ã¿ãã³ïŒ«æ®æè¬ããã³æåè¡è¬ããã¯ã«ãã¢ãªã³
ã®çµå£äœ¿çšã®ç£èŠã«é¢ããæ¬çºææ¹æ³ã«åŸã€ãŠç£
èŠããå Žåãåæ§ãªçµæãåŸããããæ°çš®ã®å»åŠ
çé害ã䌎ãåæ£è ã®è¡æž äžã«ãããç°åžžããã
ãã³ãã³æ°Žæºã第ïŒå³ã«ç€ºãã ç°åžžããããã³ãã³ã«å¯Ÿããã¢ãã¯ããã«æäœã®
調補 ãã«ãïŒïœç³»ããŠã¹ããå®å šåããã€ã³ãã®ã¢
ãžãŠãã³ãäžã«25ÎŒïœã®ããç°åžžããããã³ãã³
ãæ··åãããã®ãç®äžæ³šå°ããŠå ç«ããã30æ¥ã
ãã³37æ¥åŸã«ã10ÎŒïœã®ç°åžžããããã³ãã³ãã
é£å¡©æ°Žäžã«æ³šå ¥ãããå ç«ãããããŠã¹ã®èŸè现
èïŒïŒÃ107ïŒãšSp2ïŒïŒè¡æŒ¿çŽ°èç³»ïŒïŒÃ106ïŒ
ãšã®èåã¯ã28ïŒ ããªãšãã¬ã³ã°ãªã³ãŒã«2000ã
çšããŠ0.5mläžã§ïŒåéè¡ã€ããèåãã现èãã
ããããµã³âã¢ããããªãã³âãããžã³ãå«ã
ïŒæçµæ¿åºŠã¯ããããã1.36ïŒ0.176ïŒããã³0.38
mgïŒmlïŒRPMI 1640ïŒ20ïŒ ä»ãŠã·è¡æž ã«æžæ¿ãã
ãŠãšã«ãããïŒâïŒÃ105ã®çŽ°èæ¿åºŠã§æ¥çš®ããã
æ¥çš®ãã540ã®ãŠãšã«ã®43ïŒ ã«çŽ°èã®çè²ã芳å¯
ãããã现èãæ°é±éå¹é€åŸãã³ãããŒãå«ããŠ
ãšã«ããäžæž ãåžåŒãã該äžæž ã«ã€ããŠæãã¹â
γâã«ã«ãã ããã³ãã³æäœæŽ»æ§ãã¢ãã»ã€ã
ããéœæ¥µã®ãŠãšã«ã®çŽ°èãéžæããŠå¶éåžéæ³ã«
ããã¯ããŒã³åãããããŠåãæ¹æ³ã«ããåã¯ã
ãŒã³åããã æç°åžžããããã³ãã³æäœãåæ³ãã现èã¯ã
ç°åžžããããã³ãã³ãšå€©ç¶ããããã³ãã³ïŒä»¥
äžãåããããã³ãã³ïŒãçšããïŒåã®åºçžã€ãŒ
ã©ã€ã¶ïŒELISAïŒæ³ã§åå®ãããããããã³ã
ã³ãšãããç°åžžåããããã³ãã³ãšãã€ãšå€§ããª
åå¿æ§ã瀺ãåã¯ãéå®åžéã«ãã€ãŠã¯ããŒã³å
ãããJO1âïŒãšåœåãããã¯ããŒã³ã¯ãç°åžžã
ãããã³ãã³ã«ã¯çµåãããåããããã³ãã³ãš
ã¯æ¥µå ãåå¿ããã ãã®æäœãçæãããã¢ãã¯
ããã«æäœã¯ãåç¹ç°æ§è¡æž ãçšãããªã¯ã¿ãã
ãŒã®å ç«æ¡æ£æ³ã«ããIgG1ãšããŠå®çŸ©ãããã ã¯ããŒã³JO1âïŒã¯ATCCã«å¯èšãããHB
8638ãšããåå ¥çªå·ãä»ããããã åºé¡äººã®è²å人ã§ããããŠãŒã€ã³ã°ã©ã³ãã¡ã
ã€ã«ã«ã»ã³ã¿ãŒã¯ããã®å¹é€ç©ãçºè¡ãããç¹èš±
ã®åç¶æéã®çµäºåã«å ã«æ»ããæ»ã¬ããã«ãã
矩åãè² ããäžã€ãããç¹èš±ã®çºè¡ãATCCã«å±
ããŠãã®æç¹ã§å¯èšç©ãå¯èšæ¥ããå°ãªããšã30
幎éã¯å ¬è¡ã®çšã«äŸãåŸãããã«ãã矩åãè²
ããäžèšæç¹ãŸã§ã¯ãå¯èšç©ã¯ã37 CFR1.14ç¯
ããã³ç±³åœç¹èš±æ³112ç¯ã®æ¡ä»¶ã®äžã«ç¹èš±å±é·å®
ãžæäŸãããã JO1âïŒæäœã®ç²Ÿè£œ ã«ã«ã·ãŠç¡ãã®ç°åžžããããã³ãã³ã«ç¹ç°çãª
JO1âïŒã¯ã次ã®ããã«è¡ã€ããããããã³ãã³
ããèåã·ã¢ã³ã§æŽ»æ§åããã»ãã¢ããŒã¹
ïŒSepharoseïŒ4Bã«ã¿ã³ãã¯è³ªïŒæš¹èéãïŒmgïŒ
mlã§ã«ãããªã³ã°ããããïŒæ¬ã®ã¢ãã€ããã€ã«
ã©ã ãçšæããŠãïŒããªã¢ã«ã®EDTAã®ååšãŸ
ãã¯äžåšã§ããããã³ãã³ãã«ãããªã³ã°ãã
ãã JO1âïŒå¹é€ç©äžæž 液ãã¢ãã³ã³ïŒAmiconïŒ
PM30èã§40åã«æ¿çž®ããTBSïŒEDTAïŒïŒããª
ã¢ã«ïŒäžã«éæããããã®ç©è³ªïŒ1.5mlïŒã
TBSïŒEDTMïŒïŒmlïŒãšå¹³è¡¡ã«ããåŸããããã
ããããã³ãã³âã»ãã¢ããŒã¹ ã«ã©ã ïŒ1.0Ã
2.3cmïŒã«å ãããçµåããæäœã¯ãåãç·©è¡æ¶²
ã§ïŒæéå¹é€ããåŸãTBSïŒCa++ïŒ15ããªã¢ã«ïŒ
ã§æº¶åºããã ããããã³ãã³çµå掻æ§ããçŽæ¥çµåã€ãŒã©ã€
ã¶ïŒELISAïŒæ³ã«ãã€ãŠæž¬å®ãããæäœèª¿è£œç©
ã®é£ç¶åžé液ãããæšæºæ²ç·ãäœæããã粟補ã
ãã¢ãã¯ããã«æäœã也ç¥ã¹ã¯ããŒã¹ãçšããŠã
éæ管äžã§æ¿çž®ãã8.75ïŒ SDS ããªã¢ã¯ãªã«ã¢
ããã²ã«äžã§çŽåºŠã枬å®ãããåé¢ãããJO1â
ïŒæäœã¯ãSDSããã³ããŒãã¹ïŒDavisïŒã²ã«é»
æ°æ³³åæ³ã§ã¯åäžãã³ããšããŠç§»åããã æäœâããããã³ãã³çžäºäœçšã«å¯ŸããïŒäŸ¡éœã€
ãªã³ã®å¹æ çŽæ¥çµåã€ãŒã©ã€ã¶æ³ãçšããŠãæäœâæåé¯
äœã®è§£é¢ã«å¯ŸããCa++ãMg++ããã³Mn++ã®å¹
æãæ€èšãããããããã³ãã³ãå«ãã€ã ãã³
ïŒImmulonïŒãã¬ãŒããTBSã§ïŒåæŽæµãã
åŸã23âã§ïŒïŒ BSAïŒTBSïŒïŒããªã¢ã«EDTA
ã§30åéæŽæµãããã±ã¬ãã¯ã¹ïŒChelexïŒ100
ããã€ãªã©ããïŒBioRadïŒããå«ãã«ã©ã ãçšã
ãŠéå±ãé€ããŠããŸã€ãæ°ŽãçšããŠäœæãã
TBSã§åŸ¹åºçã«æŽæµããããšã«ãã€ãŠãEDTA
ãšæ··å ¥ããŠããéå±ãåããé€å»ããã粟補ãã
ãç¹å¥ãªæäœãã0.1ã¢ã« ã°ãªã·ã³ãPH2.5ã§æº¶
åºãããæ¢å®ã®æ¡ä»¶äžã§ãJO1âïŒæäœã®ç·ãŠã
çµç¹å¹é€ç©äžæž 液ããé€å»ãããã çµæã¯ãCa++æ¿åºŠãå¢å ãããšãæäœâæå
çžäºäœçšãæžå°ããããã«ãªãããšã瀺ããã
0.9ããªã¢ã«CaCl2ã§ãåæ倧çµåã芳枬ãããã
å¯Ÿç §çã«ãïŒããªã¢ã«MnCl2ã§åæ倧çµåã芳枬
ããããé«æ¿åºŠã®Mg++ã¯ãæäœâæåå€äœã«é
å®çãªå¹æãæããã æäœâããããã³ãã³çžäºäœçšã«å¯Ÿããã«ã«ã·ãŠ
ã ã€ãªã³ã®å¹æ ïŒããªã¢ã«CaCl2ã®ååšãŸãã¯äžåšã«ãããã
çµç¹å¹é€ç©äžæž 液äžã®JO1âïŒæäœãšããããã³
ãã³ããã³ç°åžžããããã³ãã³ãšã®çžäºäœçšãã
åºçžãµã³ããŠã€ããã€ãŒã©ã€ã¶æ³ãçšããŠè©äŸ¡ã
ããJO1âïŒæäœã¯ãã«ã«ã·ãŠã ã€ãªã³ã®ååšãŸ
ãã¯äžåšã«ãããŠãç°åžžããããã³ãã³ã«çµåã
ãããγâã«ã«ããã·ã°ã«ã¿ãã³é žãæ¬ ããç°åžž
ããããã³ãã³ã¯ãéå±çµåæ§ãæãªãããŠããŸ
ã€ãŠãããéå±ã«ãã€ãŠèªèµ·ãããæ§é ç©é·ç§»ã
è¡ããªããå¯Ÿç §çã«ãJO1âïŒæäœã¯ãEDTAã®
ååšã«ãããŠã®ã¿ããããã³ãã³ã«çµåãããïŒ
ããªã¢ã«ã®CaCl2ã®ååšã§ã¯ãæäœã®ããããã³
ãã³ãžã®çµåã¯èŠãããªãã€ãããããã®çµæ
ã¯ãç°åžžããããã³ãã³ã«ç¹ç°çãªãã®ã¢ãã¯ã
ãã«æäœãããããã³ãã³ã®ç¡ã«ã«ã·ãŠã ã³ã³ã
ãªãŒããŒã«å¯ŸããŠã³ã³ããªã¡ãŒã·ãšã³ç¹ç°æ§ã§ã
ããããšã瀺ããã ããããã³ãã³ã«å¯Ÿããæåæ§æ±ºå®åº JO1âïŒæäœãšåºçžã«çµåããç°åžžããããã³
ãã³ãšã®çžäºäœçšãæå¶ããããããã³ãã³ãã
ã³ããããã³ãã³ã®ããªãããããã©ã°ã¡ã³ãã®
èœåãã競åã€ãŒã©ã€ã¶ïŒELISAïŒæ³ãçšããŠ
è©äŸ¡ãããïŒããªã¢ã«EDTAã®ååšã§ã¯ãç°åžž
ããããã³ãã³ãã©ã°ã¡ã³ãïŒïŒâ39ïŒãã©ã°ã¡
ã³ãïŒããã³ããããã³ãã³ã¯ãJO1âïŒæäœã«
å¹æçã«çµåãããå®éšèª€å·®ã®ç¯å²å ã§ãJO1â
ïŒæäœã¯ããããã®ããªããããäžã«çŸããæå
æ§æ±ºå®åºã«åœéçã«çµåããããã«æããããå
察ã«ã15ããªã¢ã«ã®CaCl2ã®ååšã«ããããã¹â
ïŒïŒâ44ïŒããããã³ãã³ã¯ãæäœã«çµåããªã
ã€ãããããã®çµæã¯ãããããã³ãã³ããã³ç°
åžžããããã³ãã³äžã§JO1âïŒæäœãåããããŠ
ããæåæ§æ±ºå®åºãããããã³ãã³ã®NH2âæ«
æºïŒâ39ã¢ããé žæ®åºå ã«å«ãŸãããã©ã°ã¡ã³ã
ïŒïŒâ39ïŒäžã«å®å šã«è¡šãããã åçºæ§è现èçãæ€åºããããã®ç°åžžããããã³
ãã³ã«å¯Ÿããæäœã®äœ¿çš äžè¿°ã®ããã«ãããç°åžžããããã³ãã³ã«åå¿
ãäžã€åããããããã³ãã³ãšã¯æ®ãã©åå¿ããª
ãïŒããªã¯ããã«ãŸãã¯ã¢ãã¯ããã«ïŒæäœã¯ã
ããæ£è ã®è¡æ¶²ãŸãã¯ä»ã®çç©åŠçè©Šæã«ããã
ç°åžžããããã³ãã³ã®ååšãæ€åºããããå ç«å
å®æ³ã«çšããããšãã§ãããŸãç°åžžããããã³ã
ã³ã®æ€åºã«ãã€ãŠãèæ©èœäžå šã®éæãè¡ãããš
ãã§ãããæ¬åºé¡äººçã¯ãçæåŠçè©Šæäžã®ç°åžž
ããããã³ãã³ãå®éããããšã«ãã€ãŠãåçºæ§
è现èçã®èšºæãè¡ãããšãã§ããããšãèŠãåº
ããã åçºæ§è现èçã¯ãαâããšãã¿ã³ãã¯è³ªãç°
åžžãã¿ãã³B12çµåå€ããšãªããããšãã³ããã³
ç°åžžãã€ããªããŒã²ã³ã®ãããªè¿·èµ°æ§ããã³ç°æ
æ§ã¿ã³ãã¯è³ªã®åæã«é¢é£ããŠããããšãç¥ãã
ãŠããè «çã§ããããã®ãã®ã¿ã³ãã¯è³ªã®å¹Ÿã€ã
ã¯ãç¹ã«Î±âããšãã¿ã³ãã¯è³ªã¯ãåŠçããã³ç®¡
çãé©åã«ããäžã§æ©æã®äžã€æ£ç¢ºãªèšºæãéèŠ
ãªç æ°ã®èšºæããŒã«ãŒãšããŠäœ¿çšãããŠãããé«
ã¬ãã«ã®ç°åžžããããã³ãã³ã®ååšã¯ã次ã«è©³çŽ°
ã«èª¬æããããã«ãæãç¹ã§ã¯äžèšã¿ã³ãã¯è³ªã®
æããã®ãããããããåçºæ§è现èç蚺æããŒ
ã«ãŒã§ããã çæ€ã«ãã€ãŠè现èçã§ããããšã確ãããã
ã40人ã®å°æ¹Ÿäººæ£è ãš26人ã®ç±³åœäººæ£è ã«ã€ããŠ
æ€èšãããæ²»çåã«ããããã®æ£è ããè¡æž è©Šæ
ãæ¡åãããçæ€ã§ïŒ¢åè¡šé¢æåéœæ§ã®æ ¢æ§æŽ»å
æ§èçãšèšºæããã28人ã®æ£è ããã³17人ã®èè
ãå«ã転移æ§çæ£è ã«ã€ããŠãæ€èšãããè现è
çæ£è ã®å¹³å幎什ã¯ã54æã§ãã€ãã€ããããã
ã®æ£è ã®64ïŒ ã¯ãåèçè¡šé¢æäœã«éœæ§ã§ãã€
ããåèçææã®ä»ã®è¡æž ããŒã«ãŒïŒïŒ¢åèç
è¡šé¢æäœãèçã³ã¢æäœãBeåèçæåããã³
BeåèçæäœïŒãå°æ¹Ÿäººæ£è ã«ã€ããŠæž¬å®ãã
ãšããã50人äž41人ïŒ82ïŒ ïŒãåèçã«ææã
ãŠããããšãæããã«ãªã€ãã åããããã³ãã³ããã³ç°åžžããããã³ãã³
ããäžè¿°ã®ç«¶åçæŸå°å ç«åå®æ³ã§ããªã¯ããã«
æäœãçšããŠæ£è ã®è¡æž ã§æž¬å®ãããåå®éã®å€
åã¯ã10ïŒ ä»¥äžã§ãã€ããαâããšãã¿ã³ãã¯è³ª
æåããã³ïŒ¢åèçè¡šé¢æåãã競åçæŸå°å ç«
åå®æ³ïŒÎ±âããšãâRIAãããïŒïœâFetoâ
RIAKitïŒããã€ããããïŒDainabotïŒãæ±äº¬ãã
ãã³ã¢ãŠã¹ãªã¢ãããïŒAUSRIA KitïŒãã¢ãã
ã ã©ãã©ããªãŒãºïŒAbbott LaboratoriesïŒã·
ã«ãŽãã«ãã€ãŠè¡æž äžã§æž¬å®ãããããããã³ã
ã³æéãæšæºæ³ã«ãã€ãŠã¯ãšã³é žå¡©å è¡æŒ¿äžã§æž¬
å®ãããããŒã¿ããŸãšããŠãã¯ãªã³ããª
ïŒCLINFOïŒã·ã¹ãã ïŒããã¯ã¹ïŒVAXïŒ
ïŒ730ã³ã³ããŠã¿ãŒïŒã«ãã€ãŠåæããã ç°åžžããããã³ãã³ã«å¯Ÿããå€ã¯ãæ£èŠååžã«
åŸããªãã€ãã®ã§ãçµ±èšåæã«å¹Ÿäœå¹³åã®èšç®ã
åãå ¥ããã 76人ã®è现èçæ£è ã«ãããç°åžžããããã³ã
ã³æåããã³åããããã³ãã³æåã®ååžãã第
ïŒå³ã«ç€ºãïŒç°åžžããããã³ãã³ã®å€§ããã¯ïŒæ¡
ã«äºã€ãŠå€åããã®ã§ã察æ°ç®çãã§ç€ºããŠã
ãïŒããããã®æ£è ã®91ïŒ ïŒ76人äž69人ïŒã«ãç°
åžžããããã³ãã³ãæ€åºããããç·ãŠã®æ£è ã§ã®
å¹³åã¯ã900nïœïŒmlïŒç¯å²ãïŒâ67.000ïŒã§ãã€
ããç°åžžããããã³ãã³æåãšåããããã³ãã³
æåãšã®éã«ã¯ãçžé¢ã¯ãªãã€ããåããããã³
ãã³æåã®å¹³åå€ã¯ã90000±28000nïœïŒmlã§ã
ããããã¯æ£åžžè¢«éšè ã«ã€ããŠæž¬å®ããå€
ïŒ108000±19000nïœïŒmlïŒïŒïœâ0.34ãã¹ããŠãŒã
ã³ãã®ïœâæ€å®ïŒãšææå·®ã¯ãªãã€ãã è现èçæ£è ã¯ãäžè¿°ã®ããã«ãã¿ãã³ïŒ«æ¬ ä¹
çæ£è ãåããããã³ãã³æåã®å€ãäœãã®ã«æ¯
ã¹ãŠãæ£åžžã®åããããã³ãã³æåã®å€ãæã
ããããããã³ãã³æéææšãããã¿ãã³ïŒ«æ¬ ä¹
æ£è ã§ã¯äœäžããã®ã«ã66人ã®æ£è äž46人ãæ£åžž
ã§ãã€ãã ãããã®æ£è ã§ã®ç°åžžããããã³ãã³ã®äžæã
æœåšçãã¿ãã³ïŒ«æ¬ ä¹çãåæ ããŠãããšããå¯
èœæ§ãé€ããããïŒäººã®æ£è ã«ãã¿ãã³ïŒ«ïŒ20mgïŒ
ãé£ç¶ïŒæ¥ééçµå£çã«åå²æäžããïŒæ¥éç°åžž
ããããã³ãã³æåã®å€ã枬å®ãããã¿ãã³ïŒ«æ¬
ä¹çïŒäººã®æ£è ã®å€ïŒç¬¬ïŒè¡šïŒãšæ¯èŒãããè¡æž
ç°åžžããããã³ãã³æåã®å€ã¯ããããŒãæ£è ã§
ã¯ææã«ã¯å€åããªãã€ããããã¿ãã³ïŒ«æ¬ ä¹æ£
è ã§ã¯äºæããããã«æžå°ããã
ãè¡šã
ç·ãŠã®æ£è
ã«ãã¿ãã³ïŒ«ãéçµå£æäžããç°åžžã
ãããã³ãã³æåã®å€ãïŒæ¥åŸã«æž¬å®ããããã
ããŒãæ£è ã«ã¯10mgãã€é£ç¶ïŒæ¥éæäžãããã¿
ãã³ïŒ«æ¬ ä¹çæ£è ã«ã¯10mgãïŒåã ãæäžããã å€ç§çã«çã®åé€ãåããïŒåã®æ£è ã«ãã
ãŠãç°åžžããããã³ãã³ããã³Î±âããšãã¿ã³ã
ã¯è³ªã枬å®ãããåé€åã¯ãïŒåã®æ£è ã¯ãè¡æž
ã®ç°åžžããããã³ãã³å€ã¯11000nïœïŒmlã§ãã€
ãããåé€ïŒã±æåŸãŸã§ã«15nïœïŒmlã«æžå°ãã
ïŒç¬¬ïŒå³ïŒã14æåŸã«ã¯ãæ£è ã¯èšåºçããã³æŸå°
ç·åŠçã«åçºã®å åã¯ãªãç°åžžããããã³ãã³æ
åã¯æ€åºãããªããŸãŸã§ãã€ããåé€ãã17æ
åŸãç°åžžããããã³ãã³æåã®æ¿åºŠã150nïœïŒ
mlã«å¢å ããã·ãŒãã€ãŒïŒCTïŒã¹ãã€ã³ã®çµæ
ããããŒãã®åçºãèŠãããã αâããšãã¿ã³ãã¯è³ªã®å€ã¯ãèšåºççµéãšæ¥µ
å ãããçžé¢ããªãã€ããåé€åŸãαâããšãã¿
ã³ãã¯è³ªå€ã¯230ãã108nïœïŒmlã«æžå°ãã14æ
åŸã«ã¯çªç¶1147n(ãš)ïŒmlã«å¢å ãã17æåŸã«ã¯ç
ãåçºããã«ãæããã408nïœïŒmlãžãšäºåºŠç®
ã®æžå°ã瀺ããã ããäžäººã®æ£è ã§ã¯ãåé€åŸïŒé±éã§ãç°åžžã
ãããã³ãã³ã¯6000ãã150nïœïŒmlãžæžå°ãã
ïŒç¬¬ïŒå³ïŒããã®æ£è ã¯å調æ»ããªãã€ããã10æ
åŸã«èšåºçã«åçºã®å åãããäžã€ç°åžžãããã
ã³ãã³æåã®æ¿åºŠã4200nïœïŒmlãšãªã€ãŠåå ¥é¢
ããããã®æ£è ã®Î±âããšãã¿ã³ãã¯è³ªæ¿åºŠã¯ã
èšåºççµéãåæ ããã ç°åžžããããã³ãã³æåã¯ãçæ€ã§Î±âããšã
ã¿ã³ãã¯è³ªé°æ§è现èçãšèšºæãããçµç¹çååŠ
çæ³ãåãã23æã®å¥³æ§ã«ã€ããŠã枬å®ããïŒç¬¬
ïŒå³ïŒããã®æ£è ã§ã¯ãè ¹æ°Žã®æžå°ãèã®å€§ãã
ã®æžå°ãé£æ¬²ã®åäžããã³äœéã®å¢å ãªã©ã®èšåº
çå¿çãæãããç°åžžããããã³ãã³æ¿åºŠã¯ãæ²»
çåã®5500nïœïŒmlãã320nïœïŒmlãžãšæžå°ã
ãã ç°åžžããããã³ãã³æåãã28åã®ïŒ¢åèçè¡š
é¢æåéœæ§æ ¢æ§ã®æŽ»åæ§èçãåçºæ§è现èçã®
çºçã«ããé害ãšçæ€ã§èšºæãããæ£è ã«ã€ããŠ
枬å®ããïŒç¬¬ïŒå³ïŒããããã®28åã®æ£è ã§ã¯ã
ç°åžžããããã³ãã³æåæ¿åºŠã¯ãç¡èŠãåŸãçšåºŠ
ã§ãã€ãïŒå¹³åå€ã10nïœïŒmlïŒãç°åžžãããã
ã³ãã³æåããèãå«ã転移çãæãã17åã®æ£
è ïŒä¹³ç ïŒåãçµè žç ïŒåãã¹ã€èç ïŒ
åãèºç ïŒåããªã³ãè « ïŒåãèµ·ç¹äžæã®è º
ç ïŒåïŒã«ã€ããŠã枬å®ãããšãããæåã®è¡
æž æ¿åºŠã42nïœïŒmlã®å¹³åå€ã§å¢å ããã åçºæ§è现èçæ£è ã®67ïŒ ãã300nïœïŒml以
äžã®ç°åžžããããã³ãã³æ¿åºŠãæãããããã¯ã
æ ¢æ§ã®æŽ»åæ§èçã®ç·ãŠã®æ£è ãäžäººãé€ã転移
çæ£è ããã³ä»¥åæ€èšããæ¥æ§èçãšè硬å€ã®æ£
è ã®90ïŒ ã«ãããŠæž¬å®ããç°åžžããããã³ãã³ã®
æ¿åºŠãè¶ããŠãããïŒãã©ã³ãã€ãŒã
ïŒBlanchardïŒçã1981幎ãããŠãŒ ã€ã³ã°ã©ã³
ã ãžã€ãŒãã« ãªã ã¡ãã€ã·ã³ïŒNew
England JOurnal of MedicineïŒã第305å·»ã242
é ïŒã αâããšãã¿ã³ãã¯è³ªæåããè现èçæ£è ã§
枬å®ããŠãç°åžžããããã³ãã³æåã«å¯ŸããŠãã
ããããïŒç¬¬ïŒå³ïŒãïŒåã®æåã®éã«ã¯ãæ®ã©
çžé¢ããªãã€ãïŒïœïŒ0.3ïŒã400nïœïŒml以äžã®Î±
âããšãã¿ã³ãã¯è³ªæåæ¿åºŠã¯ãä»ã®æ®ã©ã®æªæ§
ããã³éæªæ§çŸæ£ã«ãããŠäžæããããšãå ±åã
ããŠããã®ã§ãè现èçã匷ã瀺åæ瀺ãããã®
ã§ãããšå ±åããããäžèš76åã®æ£è ã®ãã¡48å
ïŒ63ïŒ ïŒã§ã¯ãαâããšãã¿ã³ãã¯è³ªæåæ¿åºŠã¯
400nïœïŒml以äžã§ããããŸã28åã¯äœæ¿åºŠã§ã
ãããã®16åïŒ57ïŒ ïŒã¯ç°åžžããããã³ãã³æ¿åºŠ
ã¯300nïœïŒml以äžã§ãã€ããäž¡åæçµæããŸãš
ãããšã64åïŒ84ïŒ ïŒã®æ£è ã§è¡æž æåã®äžæ¹ãŸ
ãã¯äž¡æ¹ã®æ¿åºŠãé«ããåçºæ§è现èçã匷ãæ
瀺ããã αâããšãã¿ã³ãã¯è³ªããã³ç°åžžããããã³ã
ã³æåæ¿åºŠã¯ãèçè¡šé¢æåã®ååšãŸãã¯äžåšã«
ã¯é¢ä¿ããªãã€ããè¡šé¢æåéœæ§ã®æ£è ã§ã¯ãè¡
æž ã®ç°åžžããããã³ãã³ã®å¹³åå€ã¯ïŒ974nïœïŒ
mlïŒç¯å²ãïŒâ67000ïŒã§ãããè¡šé¢æåé°æ§ã®
æ£è ã§ã¯ã805nïœïŒmlïŒç¯å²ãïŒâ23000ïŒã§ã
ã€ãã äžèšçµæã¯ãç°åžžããããã³ãã³åçºæ§è现è
çã«å¯Ÿããè¡æž è «çããŒã«ãŒã§ããããšã瀺ããŠ
ããããã®æåã¯ãããããŒãæ£è ã®å€§éšåã«å
åšãããã¿ãã³ïŒ«ã®éçµå£æäžã«ãã€ãŠãæ¶å€±ã
ãªããããæ ããããã®æ£è ã¯ãã¿ãã³ïŒ«æ¬ ä¹ç
ã§ã¯ãªããæŽã«ãç°åžžããããã³ãã³æåã¯ãè «
çãåé€ãããååŠçæ³ã«ãã€ãŠæ¶å€±ãŸãã¯æžå°
ããããã®èšŒæ ã¯ç°åžžããããã³ãã³ããã¿ãã³
äŸåã«ã«ããã·ã«åã«ãããããããŒãèªçºæ¬
æããçããŠããããšãæ¯æããã äžèšçµæã¯ãç°åžžããããã³ãã³ã®å€§äžæãã
åçºæ§è现èçãšèèçãå«ãä»ã®èé害ãšãåº
å¥ããã®ã«åœ¹ç«ã€ããšã瀺ããŠãããããã¯ãã
ããã³ãã³åæã«ã€ããŠç¥ãããŠããããšãšé©å
ããè现èãããããã³ãã³ãåæããŠã«ã«ãã
ã·ã«åããã ãã§ãããç°åžžããããã³ãã³æå
ã®å€§äžæãè现èã®æªæ§å€æã«ã ãèµ·ãããæ¥æ§
èçãæ ¢æ§æŽ»åæ§èçããã³è硬å€ã®ãããªéæª
æ§è现èçŸæ£ã«èŠãããäœæ¿åºŠã®ç°åžžããããã³
ãã³ã¯ãæã«ã¯ãããã®çŸæ£ãšè现èçãåºå¥ã
ãããšãå°é£ã«ããã®ã§ãè¡æž ïŒmlåœããçŽ
300nïœïŒãŸãã¯åžéãçšããå Žåã«ã¯ãåœéïŒ
ã®ããå€ãããããŒãã匷ãæ瀺ãããã®ãšããŠ
瀺ãããããã°ãã°è现èçã®åé§äœãšããŠã®æ ¢
æ§æŽ»åæ§èçãç¹åŸŽã¥ããéåžžã«äœæ¿åºŠã®ç°åžžã
ãããã³ãã³ã¯ãç°åžžããããã³ãã³æåã芳å¯
ããŠããæ ¢æ§æŽ»åæ§èçæ£è ã§ã®æªæ§å€æãæ€åº
ããããšãã§ããã αâããšã¿ã³ãã¯è³ªæåããã³ç°åžžããããã³
ãã³æåã¯ãããããè现èçæ£è ãçŽïŒåã®ïŒ
ã®é«ç¢ºçã§åå®ããããšãã§ããããããã®æå
ã¯ãæªæ§è现èã«ãããç°ãªãçååŠççµè·¯ã®å€
æŽã枬å®ãããäžç·ã«çšããå Žåã«ã¯ãäž¡è©Šéšã¯
åäžã®è «çããŒã«ãŒã§åŸããããããå€ãã®æ å ±
ãæäŸããããã¿ãã³ïŒ«æ¬ ä¹çã蚺æçèå¯ãšã
ãŠé€å€ããããšãã§ããå Žåã«ã¯ããããïŒã€ã®
è©Šéšã¯ãåçºæ§è现èçæ£è ã®84ïŒ ãåå®ããã
ãšãã§ãããã®çŸæ£ã®è£å©çè «çããŒã«ãŒã§ã
ãã
ãããã³ãã³æåã®å€ãïŒæ¥åŸã«æž¬å®ããããã
ããŒãæ£è ã«ã¯10mgãã€é£ç¶ïŒæ¥éæäžãããã¿
ãã³ïŒ«æ¬ ä¹çæ£è ã«ã¯10mgãïŒåã ãæäžããã å€ç§çã«çã®åé€ãåããïŒåã®æ£è ã«ãã
ãŠãç°åžžããããã³ãã³ããã³Î±âããšãã¿ã³ã
ã¯è³ªã枬å®ãããåé€åã¯ãïŒåã®æ£è ã¯ãè¡æž
ã®ç°åžžããããã³ãã³å€ã¯11000nïœïŒmlã§ãã€
ãããåé€ïŒã±æåŸãŸã§ã«15nïœïŒmlã«æžå°ãã
ïŒç¬¬ïŒå³ïŒã14æåŸã«ã¯ãæ£è ã¯èšåºçããã³æŸå°
ç·åŠçã«åçºã®å åã¯ãªãç°åžžããããã³ãã³æ
åã¯æ€åºãããªããŸãŸã§ãã€ããåé€ãã17æ
åŸãç°åžžããããã³ãã³æåã®æ¿åºŠã150nïœïŒ
mlã«å¢å ããã·ãŒãã€ãŒïŒCTïŒã¹ãã€ã³ã®çµæ
ããããŒãã®åçºãèŠãããã αâããšãã¿ã³ãã¯è³ªã®å€ã¯ãèšåºççµéãšæ¥µ
å ãããçžé¢ããªãã€ããåé€åŸãαâããšãã¿
ã³ãã¯è³ªå€ã¯230ãã108nïœïŒmlã«æžå°ãã14æ
åŸã«ã¯çªç¶1147n(ãš)ïŒmlã«å¢å ãã17æåŸã«ã¯ç
ãåçºããã«ãæããã408nïœïŒmlãžãšäºåºŠç®
ã®æžå°ã瀺ããã ããäžäººã®æ£è ã§ã¯ãåé€åŸïŒé±éã§ãç°åžžã
ãããã³ãã³ã¯6000ãã150nïœïŒmlãžæžå°ãã
ïŒç¬¬ïŒå³ïŒããã®æ£è ã¯å調æ»ããªãã€ããã10æ
åŸã«èšåºçã«åçºã®å åãããäžã€ç°åžžãããã
ã³ãã³æåã®æ¿åºŠã4200nïœïŒmlãšãªã€ãŠåå ¥é¢
ããããã®æ£è ã®Î±âããšãã¿ã³ãã¯è³ªæ¿åºŠã¯ã
èšåºççµéãåæ ããã ç°åžžããããã³ãã³æåã¯ãçæ€ã§Î±âããšã
ã¿ã³ãã¯è³ªé°æ§è现èçãšèšºæãããçµç¹çååŠ
çæ³ãåãã23æã®å¥³æ§ã«ã€ããŠã枬å®ããïŒç¬¬
ïŒå³ïŒããã®æ£è ã§ã¯ãè ¹æ°Žã®æžå°ãèã®å€§ãã
ã®æžå°ãé£æ¬²ã®åäžããã³äœéã®å¢å ãªã©ã®èšåº
çå¿çãæãããç°åžžããããã³ãã³æ¿åºŠã¯ãæ²»
çåã®5500nïœïŒmlãã320nïœïŒmlãžãšæžå°ã
ãã ç°åžžããããã³ãã³æåãã28åã®ïŒ¢åèçè¡š
é¢æåéœæ§æ ¢æ§ã®æŽ»åæ§èçãåçºæ§è现èçã®
çºçã«ããé害ãšçæ€ã§èšºæãããæ£è ã«ã€ããŠ
枬å®ããïŒç¬¬ïŒå³ïŒããããã®28åã®æ£è ã§ã¯ã
ç°åžžããããã³ãã³æåæ¿åºŠã¯ãç¡èŠãåŸãçšåºŠ
ã§ãã€ãïŒå¹³åå€ã10nïœïŒmlïŒãç°åžžãããã
ã³ãã³æåããèãå«ã転移çãæãã17åã®æ£
è ïŒä¹³ç ïŒåãçµè žç ïŒåãã¹ã€èç ïŒ
åãèºç ïŒåããªã³ãè « ïŒåãèµ·ç¹äžæã®è º
ç ïŒåïŒã«ã€ããŠã枬å®ãããšãããæåã®è¡
æž æ¿åºŠã42nïœïŒmlã®å¹³åå€ã§å¢å ããã åçºæ§è现èçæ£è ã®67ïŒ ãã300nïœïŒml以
äžã®ç°åžžããããã³ãã³æ¿åºŠãæãããããã¯ã
æ ¢æ§ã®æŽ»åæ§èçã®ç·ãŠã®æ£è ãäžäººãé€ã転移
çæ£è ããã³ä»¥åæ€èšããæ¥æ§èçãšè硬å€ã®æ£
è ã®90ïŒ ã«ãããŠæž¬å®ããç°åžžããããã³ãã³ã®
æ¿åºŠãè¶ããŠãããïŒãã©ã³ãã€ãŒã
ïŒBlanchardïŒçã1981幎ãããŠãŒ ã€ã³ã°ã©ã³
ã ãžã€ãŒãã« ãªã ã¡ãã€ã·ã³ïŒNew
England JOurnal of MedicineïŒã第305å·»ã242
é ïŒã αâããšãã¿ã³ãã¯è³ªæåããè现èçæ£è ã§
枬å®ããŠãç°åžžããããã³ãã³æåã«å¯ŸããŠãã
ããããïŒç¬¬ïŒå³ïŒãïŒåã®æåã®éã«ã¯ãæ®ã©
çžé¢ããªãã€ãïŒïœïŒ0.3ïŒã400nïœïŒml以äžã®Î±
âããšãã¿ã³ãã¯è³ªæåæ¿åºŠã¯ãä»ã®æ®ã©ã®æªæ§
ããã³éæªæ§çŸæ£ã«ãããŠäžæããããšãå ±åã
ããŠããã®ã§ãè现èçã匷ã瀺åæ瀺ãããã®
ã§ãããšå ±åããããäžèš76åã®æ£è ã®ãã¡48å
ïŒ63ïŒ ïŒã§ã¯ãαâããšãã¿ã³ãã¯è³ªæåæ¿åºŠã¯
400nïœïŒml以äžã§ããããŸã28åã¯äœæ¿åºŠã§ã
ãããã®16åïŒ57ïŒ ïŒã¯ç°åžžããããã³ãã³æ¿åºŠ
ã¯300nïœïŒml以äžã§ãã€ããäž¡åæçµæããŸãš
ãããšã64åïŒ84ïŒ ïŒã®æ£è ã§è¡æž æåã®äžæ¹ãŸ
ãã¯äž¡æ¹ã®æ¿åºŠãé«ããåçºæ§è现èçã匷ãæ
瀺ããã αâããšãã¿ã³ãã¯è³ªããã³ç°åžžããããã³ã
ã³æåæ¿åºŠã¯ãèçè¡šé¢æåã®ååšãŸãã¯äžåšã«
ã¯é¢ä¿ããªãã€ããè¡šé¢æåéœæ§ã®æ£è ã§ã¯ãè¡
æž ã®ç°åžžããããã³ãã³ã®å¹³åå€ã¯ïŒ974nïœïŒ
mlïŒç¯å²ãïŒâ67000ïŒã§ãããè¡šé¢æåé°æ§ã®
æ£è ã§ã¯ã805nïœïŒmlïŒç¯å²ãïŒâ23000ïŒã§ã
ã€ãã äžèšçµæã¯ãç°åžžããããã³ãã³åçºæ§è现è
çã«å¯Ÿããè¡æž è «çããŒã«ãŒã§ããããšã瀺ããŠ
ããããã®æåã¯ãããããŒãæ£è ã®å€§éšåã«å
åšãããã¿ãã³ïŒ«ã®éçµå£æäžã«ãã€ãŠãæ¶å€±ã
ãªããããæ ããããã®æ£è ã¯ãã¿ãã³ïŒ«æ¬ ä¹ç
ã§ã¯ãªããæŽã«ãç°åžžããããã³ãã³æåã¯ãè «
çãåé€ãããååŠçæ³ã«ãã€ãŠæ¶å€±ãŸãã¯æžå°
ããããã®èšŒæ ã¯ç°åžžããããã³ãã³ããã¿ãã³
äŸåã«ã«ããã·ã«åã«ãããããããŒãèªçºæ¬
æããçããŠããããšãæ¯æããã äžèšçµæã¯ãç°åžžããããã³ãã³ã®å€§äžæãã
åçºæ§è现èçãšèèçãå«ãä»ã®èé害ãšãåº
å¥ããã®ã«åœ¹ç«ã€ããšã瀺ããŠãããããã¯ãã
ããã³ãã³åæã«ã€ããŠç¥ãããŠããããšãšé©å
ããè现èãããããã³ãã³ãåæããŠã«ã«ãã
ã·ã«åããã ãã§ãããç°åžžããããã³ãã³æå
ã®å€§äžæãè现èã®æªæ§å€æã«ã ãèµ·ãããæ¥æ§
èçãæ ¢æ§æŽ»åæ§èçããã³è硬å€ã®ãããªéæª
æ§è现èçŸæ£ã«èŠãããäœæ¿åºŠã®ç°åžžããããã³
ãã³ã¯ãæã«ã¯ãããã®çŸæ£ãšè现èçãåºå¥ã
ãããšãå°é£ã«ããã®ã§ãè¡æž ïŒmlåœããçŽ
300nïœïŒãŸãã¯åžéãçšããå Žåã«ã¯ãåœéïŒ
ã®ããå€ãããããŒãã匷ãæ瀺ãããã®ãšããŠ
瀺ãããããã°ãã°è现èçã®åé§äœãšããŠã®æ ¢
æ§æŽ»åæ§èçãç¹åŸŽã¥ããéåžžã«äœæ¿åºŠã®ç°åžžã
ãããã³ãã³ã¯ãç°åžžããããã³ãã³æåã芳å¯
ããŠããæ ¢æ§æŽ»åæ§èçæ£è ã§ã®æªæ§å€æãæ€åº
ããããšãã§ããã αâããšã¿ã³ãã¯è³ªæåããã³ç°åžžããããã³
ãã³æåã¯ãããããè现èçæ£è ãçŽïŒåã®ïŒ
ã®é«ç¢ºçã§åå®ããããšãã§ããããããã®æå
ã¯ãæªæ§è现èã«ãããç°ãªãçååŠççµè·¯ã®å€
æŽã枬å®ãããäžç·ã«çšããå Žåã«ã¯ãäž¡è©Šéšã¯
åäžã®è «çããŒã«ãŒã§åŸããããããå€ãã®æ å ±
ãæäŸããããã¿ãã³ïŒ«æ¬ ä¹çã蚺æçèå¯ãšã
ãŠé€å€ããããšãã§ããå Žåã«ã¯ããããïŒã€ã®
è©Šéšã¯ãåçºæ§è现èçæ£è ã®84ïŒ ãåå®ããã
ãšãã§ãããã®çŸæ£ã®è£å©çè «çããŒã«ãŒã§ã
ãã
第ïŒå³ã¯ãæ°çš®ã®å»åŠçé害ã䌎ãæ£è
ã«ãã
ã倩ç¶ããããã³ãã³ããã³ç°åžžããããã³ãã³
ã®è¡æž æ¿åºŠã瀺ãã°ã©ãã§ããã 第ïŒå³ã¯ããã¿ãã³ïŒ«æ¬ ä¹çã䌎ãæ£è ã«ãã
ãŠãã¿ãã³ïŒ«çæ³ã倩ç¶ããããã³ãã³ããã³ç°
åžžããããã³ãã³ã«äžãã圱é¿ã瀺ãã°ã©ãã§ã
ãã第ïŒå³ã¯ãåçºæ§è现èçã䌎ã76人ã®æ£è
ã«ãããç°åžžããããã³ãã³ããã³å€©ç¶ãããã
ã³ãã³ã®è¡æž æ¿åºŠã瀺ãã°ã©ãã§ããã第ïŒå³
ã¯ãèçæ£è ïŒäººã«ãããç°åžžããããã³ãã³
ïŒé»ãã«ïŒããã³Î±âããšããããã€ã³ã®è¡æž æ¿
床ïŒçœäžžïŒã瀺ãã°ã©ãã§ãããæ£è åã³ïŒ¢ã¯
å€ç§çã«è «çãåé€ããæ£è ã§ãããæ£è ã¯æ··
åååŠçæ³ãåããŠããè ã§ãããäžè²«ããŠ10n
ïœïŒmlããäœã¬ãã«ã®Î±âããšããããã€ã³ãæ
ããã第ïŒå³ã¯ãïŒçš®ã®ç°ãªãèèé害ã䌎ãå
æ£è ã«ãããç°åžžããããã³ãã³ã®è¡æž æ¿åºŠã瀺
ãã°ã©ãã§ããã第ïŒå³ã¯ãèçæ£è 76人ã«ãã
ãç°åžžããããã³ãã³ããã³Î±âããšããããã€
ã³ã®è¡æž æ¿åºŠã瀺ãã°ã©ãã§ãããäž¡æåã®å€ã¯
察æ°ã§ç€ºãããäž¡æåã®å€ã®çžé¢æ§ã¯å°ã§ãã€
ãã第ïŒå³ã¯ãåçš®ã®å»åŠçé害ã䌎ãåæ£è ã®
è¡æž äžã«ãããç°åžžããããã³ãã³æ°Žæºã瀺ãã°
ã©ãã§ããã
ã倩ç¶ããããã³ãã³ããã³ç°åžžããããã³ãã³
ã®è¡æž æ¿åºŠã瀺ãã°ã©ãã§ããã 第ïŒå³ã¯ããã¿ãã³ïŒ«æ¬ ä¹çã䌎ãæ£è ã«ãã
ãŠãã¿ãã³ïŒ«çæ³ã倩ç¶ããããã³ãã³ããã³ç°
åžžããããã³ãã³ã«äžãã圱é¿ã瀺ãã°ã©ãã§ã
ãã第ïŒå³ã¯ãåçºæ§è现èçã䌎ã76人ã®æ£è
ã«ãããç°åžžããããã³ãã³ããã³å€©ç¶ãããã
ã³ãã³ã®è¡æž æ¿åºŠã瀺ãã°ã©ãã§ããã第ïŒå³
ã¯ãèçæ£è ïŒäººã«ãããç°åžžããããã³ãã³
ïŒé»ãã«ïŒããã³Î±âããšããããã€ã³ã®è¡æž æ¿
床ïŒçœäžžïŒã瀺ãã°ã©ãã§ãããæ£è åã³ïŒ¢ã¯
å€ç§çã«è «çãåé€ããæ£è ã§ãããæ£è ã¯æ··
åååŠçæ³ãåããŠããè ã§ãããäžè²«ããŠ10n
ïœïŒmlããäœã¬ãã«ã®Î±âããšããããã€ã³ãæ
ããã第ïŒå³ã¯ãïŒçš®ã®ç°ãªãèèé害ã䌎ãå
æ£è ã«ãããç°åžžããããã³ãã³ã®è¡æž æ¿åºŠã瀺
ãã°ã©ãã§ããã第ïŒå³ã¯ãèçæ£è 76人ã«ãã
ãç°åžžããããã³ãã³ããã³Î±âããšããããã€
ã³ã®è¡æž æ¿åºŠã瀺ãã°ã©ãã§ãããäž¡æåã®å€ã¯
察æ°ã§ç€ºãããäž¡æåã®å€ã®çžé¢æ§ã¯å°ã§ãã€
ãã第ïŒå³ã¯ãåçš®ã®å»åŠçé害ã䌎ãåæ£è ã®
è¡æž äžã«ãããç°åžžããããã³ãã³æ°Žæºã瀺ãã°
ã©ãã§ããã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ ãã¹âγâã«ã«ããã· ããããããã³ãã³
ãšåå¿ãäžã€ã«ã«ã·ãŠã ã€ãªã³ã®ååšã§ãã倩ç¶
ããããã³ãã³ãšå®è³ªçã«äžåå¿æ§ã§ããããšã
ç¹åŸŽãšãããã¢ãã¯ããã«æäœã ïŒ ã«ã«ã·ãŠã ã€ãªã³ã®ååšã«ãããŠãåèšãã¹
âγâã«ã«ããã· ããããããã³ãã³ãšåå¿ã
ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®ã¢ãã¯ããã«æ
äœã ïŒ ã«ã«ã·ãŠã ã€ãªã³ã®äžåšã«ãããŠããã倩ç¶
ããããã³ãã³ãšåå¿ãããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒ
é èšèŒã®ã¢ãã¯ããã«æäœã ïŒ çç©åŠçè©Šæã«ãããŠããã ãã¹âγâã«
ã«ããã· ããããã³ãã³ã®ååšãæ€åºããæ¹æ³
ã«ãããŠãåèšè©Šæããã¹âγâã«ã«ããã· ã
ãããããã³ãã³ãšåå¿ãäžã€ã«ã«ã·ãŠã ã€ãªã³
ã®ååšã§ãã倩ç¶ããããã³ãã³ãšå®è³ªçã«äžå
å¿æ§ã§ããããšãç¹åŸŽãšãããã¢ãã¯ãã«æäœãš
æ¥è§Šãããåèšãã¹âγâã«ã«ããã· ãããã
ã³ãã³ãšåèšã¢ãã¯ããã«æäœãšã®è€åäœããå
èšè©Šæäžã«ãããåèšãã¹âγâã«ã«ããã· ã
ãããã³ãã³ã®ååšã®ææšãšããŠæ€åºããããšã
ç¹åŸŽãšããæ¹æ³ã ïŒ åèšè€åäœããåèšè©Šæäžã«ãããåèšãã¹
âγâã«ã«ããã· ããããã³ãã³ã®å®éç尺床
ãšããŠæž¬å®ãããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®æ¹
æ³ã ïŒ åèšæäœãæ€åºå¯èœãªæšèã§æšèãããç¹èš±
è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®æ¹æ³ã
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US661187 | 1984-10-15 | ||
| US06/661,187 US4769320A (en) | 1982-07-27 | 1984-10-15 | Immunoassay means and methods useful in human native prothrombin and human abnormal prothorombin determinations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS61117457A JPS61117457A (ja) | 1986-06-04 |
| JPH0441000B2 true JPH0441000B2 (ja) | 1992-07-06 |
Family
ID=24652562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP60229763A Granted JPS61117457A (ja) | 1984-10-15 | 1985-10-15 | ã¢ãã¯ãâãã«æäœ |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US4769320A (ja) |
| EP (1) | EP0182495B1 (ja) |
| JP (1) | JPS61117457A (ja) |
| AT (1) | ATE52141T1 (ja) |
| DE (1) | DE3577233D1 (ja) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11359009B2 (en) | 2015-12-25 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| US11608374B2 (en) | 2017-01-30 | 2023-03-21 | Chugai Seiyaku Kabushiki Kaisha | Anti-sclerostin antibodies and methods of use |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6258938B1 (en) * | 1983-10-28 | 2001-07-10 | Ne Medical Center Hospital, Inc. | Method for the purification and isolation of blood clotting proteins using conformation specific antibodies |
| DE3727610A1 (de) * | 1987-08-19 | 1989-03-02 | Behringwerke Ag | Synthetische peptide, gegen diese gerichtete antikoerper und deren verwendung |
| US5147779A (en) * | 1988-06-01 | 1992-09-15 | Miles Inc. | Method for evaluating immunogenicity |
| US5217870A (en) * | 1989-04-28 | 1993-06-08 | Biogen, Inc. | Monoclonal antibodies against CDX |
| US5272263A (en) * | 1989-04-28 | 1993-12-21 | Biogen, Inc. | DNA sequences encoding vascular cell adhesion molecules (VCAMS) |
| US5532136A (en) * | 1993-06-22 | 1996-07-02 | Bionebraska, Inc. | Monoclonal antibody assay and kit for detecting metal cations in body fluids |
| US20020040008A1 (en) * | 1995-01-24 | 2002-04-04 | Wagner Denisa D. | Method for treating and preventing atherosclerosis |
| WO1998005055A1 (fr) * | 1996-07-27 | 1998-02-05 | Moriyama Sangyo Kabushiki Kaisha | Dispositif emetteur de lumiere, dispositif de douille et dispositif d'eclairage |
| US5935802A (en) * | 1998-08-10 | 1999-08-10 | Evanston Northwestern Healthcare Research Institute | Method of assaying a blood sample for prothrombin |
| CA2378711A1 (en) * | 1999-08-14 | 2001-02-22 | November Aktiengesellschaft Gesellschaft Fur Molekulare Medizin | Method for indirectly determining the blood-clotting status |
| DE19941447C2 (de) * | 1999-08-14 | 2002-06-27 | November Ag Molekulare Medizin | Verfahren zur indirekten Bestimmung des Blutgerinnungsstatus |
| AU2003296086A1 (en) * | 2002-12-26 | 2004-07-22 | Nitto Boseki Co., Ltd. | Immunoassay method and kit to be used therein |
| LT2708559T (lt) | 2008-04-11 | 2018-06-11 | Chugai Seiyaku Kabushiki Kaisha | AntigenÄ suriÅ¡anti molekulÄ, galinti pakartotinai prisijungti prie dviejų ar daugiau antigeno molekulių |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| US8283162B2 (en) * | 2009-03-10 | 2012-10-09 | Abbott Laboratories | Antibodies relating to PIVKAII and uses thereof |
| EP2647706B1 (en) * | 2010-11-30 | 2023-05-17 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
| MX352889B (es) | 2011-02-25 | 2017-12-13 | Chugai Pharmaceutical Co Ltd | Anticuerpo de fc especifico para fcyriib. |
| TW201817745A (zh) | 2011-09-30 | 2018-05-16 | æ¥åäžå€è£œè¥è¡ä»œæéå ¬åž | å ·æä¿é²æåæž é€ä¹ïŒŠïœïŒ²ïœçµååçæ²»çæ§æåçµååå |
| US20150050269A1 (en) | 2011-09-30 | 2015-02-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
| SG11201700841QA (en) | 2014-12-19 | 2017-03-30 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
| MY183415A (en) | 2014-12-19 | 2021-02-18 | Chugai Pharmaceutical Co Ltd | Anti-c5 antibodies and methods of use |
| KR102605798B1 (ko) | 2015-02-05 | 2023-11-23 | ì¶ê°ìŽ ìžìŽìŒì¿ ê°ë¶ìí€ê°ìŽì€ | ìŽìš ëë ìì¡Žì íì ê²°í© ëë©ìžì í¬íšíë í첎, Fc ìì ê°ë³ì²Ž, IL-8ì ê²°í©íë í첎, ë° ê·žë€ì ì¬ì© |
| BR112017014067B1 (pt) | 2015-02-27 | 2021-01-12 | Chugai Seiyaku Kabushiki Kaisha | usos de um anticorpo receptor de il-6 para no tratamento de doenças relacionadas a il-6 |
| CN107727864A (zh) * | 2016-07-01 | 2018-02-23 | éŠéœå»ç§å€§åŠéå±å京äœå®å»é¢ | äžç§æ£æµè¡æž äžåŒåžžè±çŸ§åè¡é ¶åçèçœè¯çãè¯åçåå ¶å¶å€æ¹æ³ |
| MX2019001448A (es) | 2016-08-05 | 2019-09-13 | Chugai Pharmaceutical Co Ltd | Composicion para profilaxis o tratamiento de enfermedades relacionadas con interleucina 8 (il-8). |
| JP7185884B2 (ja) | 2017-05-02 | 2022-12-08 | åœç«ç 究éçºæ³äººåœç«ç²Ÿç¥ã»ç¥çµå»çç 究ã»ã³ã¿ãŒ | ïœïŒïŒåã³å¥œäžçã®é¢é£ããçŸæ£ã®æ²»çå¹æã®äºæž¬åã³å€å®æ¹æ³ |
| WO2019161491A1 (en) | 2018-02-20 | 2019-08-29 | Prominent Medical Inc. | Aluminum oxide surfaces and interface molecules |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6060557A (ja) * | 1983-09-13 | 1985-04-08 | Eisai Co Ltd | ïœïœïœïœâïŒã®æž¬å®æ¹æ³ããã³è©Šè¬ |
-
1984
- 1984-10-15 US US06/661,187 patent/US4769320A/en not_active Expired - Lifetime
-
1985
- 1985-10-15 AT AT85307407T patent/ATE52141T1/de not_active IP Right Cessation
- 1985-10-15 EP EP85307407A patent/EP0182495B1/en not_active Expired - Lifetime
- 1985-10-15 DE DE8585307407T patent/DE3577233D1/de not_active Expired - Fee Related
- 1985-10-15 JP JP60229763A patent/JPS61117457A/ja active Granted
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11359009B2 (en) | 2015-12-25 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| US11608374B2 (en) | 2017-01-30 | 2023-03-21 | Chugai Seiyaku Kabushiki Kaisha | Anti-sclerostin antibodies and methods of use |
Also Published As
| Publication number | Publication date |
|---|---|
| US4769320A (en) | 1988-09-06 |
| ATE52141T1 (de) | 1990-05-15 |
| DE3577233D1 (de) | 1990-05-23 |
| JPS61117457A (ja) | 1986-06-04 |
| EP0182495B1 (en) | 1990-04-18 |
| EP0182495A1 (en) | 1986-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH0441000B2 (ja) | ||
| Weitz et al. | Des-γ-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review | |
| Miletich et al. | Human plasma protein Z antigen: range in normal subjects and effect of warfarin therapy | |
| Stockigt et al. | Determination of plasma renin concentration by angiotensin I immunoassay: diagnostic import of precise measurement of subnormal renin in hyperaldosteronism | |
| RU2137130C1 (ru) | СпПÑПб ÑаММегП ПпÑеЎелеМОÑ, ПпÑÐµÐŽÐµÐ»ÐµÐœÐžÑ ÑÑжеÑÑО Ð·Ð°Ð±ÐŸÐ»ÐµÐ²Ð°ÐœÐžÑ Ðž ПÑеМка пÑПÑеÑÑа леÑÐµÐœÐžÑ ÑепÑОÑа, а Ñакже ÑÑеЎÑÑва ÐŽÐ»Ñ ÐŸÑÑÑеÑÑÐ²Ð»ÐµÐœÐžÑ ÑказаММПгП ÑпПÑПба | |
| Nossel et al. | Measurement of fibrinopeptide A in human blood | |
| Amiral et al. | Application of enzyme immunoassays to coagulation testing. | |
| Shuman et al. | The measurement of thrombin in clotting blood by radioimmunoassay. | |
| GrÞndahl-Hansen et al. | Sensitive and specific enzyme-linked immunosorbent assay for urokinase-type plasminogen activator and its application to plasma from patients with breast cancer | |
| KR0148619B1 (ko) | Pivka-xì ìž¡ì ë°©ë² ë° ìž¡ì ììœ | |
| Darras et al. | Measurement of urokinase-type plasminogen activator (u-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies | |
| EP0540573A1 (en) | ANALYSIS OF THE PROSTATE SPECIFIC ANTIGEN (PSA) IN THE FREE STATE AND IN THE COMPLEX FORMING STATE. | |
| FI109204B (fi) | ImmuunimÀÀrityksiÀ ja monoklonaalisia vasta-aineita protrombiiniaktivaatiopeptideille ja niiden hajoamistuotteille | |
| Lertora et al. | Studies on a radioimmunoassay for human erythropoietin | |
| Gordon et al. | Specific and sensitive determination of fibrinogen-degradation products by radioimmunoassay | |
| JP3053503B2 (ja) | 骚ãã匱æ§ãšéªšç²ãããç骚æã®å±éºæ§ã®æ€æ»æ¹æ³ | |
| US5252712A (en) | Purified antibodies which specifically bind human abnormal prothrombin | |
| JPH02112763A (ja) | å¯æº¶æ§æ©ãããã£ããªã³éåäœã®ã¢ãã»ã€ | |
| Fareed et al. | Impact of automation on the quantitation of low molecular weight markers of hemostatic defects | |
| JPS63258898A (ja) | ããâ²èµâŒãã¹ããªãâãŒïœâ²äžïŒâŒã«å¯Ÿããã¢ãã¯ãâãã«æäœããã®è£œé æ³ã該ã¢ãã¯ãâãã«æäœç£çãã€ããªãâãããã³è©²ã¢ãã¯ãâãã«æäœãçšããããâ²èµâŒãã¹ããªãâãŒïœâ²äžïŒâŒã®æž¬å®æ¹æ³ | |
| RuizâArguelles et al. | Serum antibodies to distinct epitopes of the tissueâtype plasminogen activator (tâPA) in patients with systemic lupus erythematosus | |
| Chen et al. | Radioimmunoassay of fibrinogen-fibrin degradation products: assay for fragment E-related neoantigen-methodological aspects | |
| Church et al. | Discrimination of normal and abnormal prothrombin and protein C in plasma using a calcium ion-inhibited monoclonal antibody to a common epitope on several vitamin K-dependent proteins | |
| Walenga et al. | Performance characteristics of a simple radioimmunoassay for fibrinopeptide A | |
| Matsumoto et al. | Increased serum type IV collagen peptide in carbon tetrachlorideâtreated rats |